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 i 
ABSTRACT 
Type 2 diabetes affects approximately 7.3% of Americans, leading to debilitating and 
life-threatening comorbidities. Estrogen and testosterone levels have been linked to 
inflammatory and oxidative stress markers, as well as glucose and insulin concentrations. 
The present study was designed to determine the link between sex differences, glucose 
control, and inflammation and oxidative stress related to daily almond ingestion among 
subjects with type 2 diabetes. Subjects were randomized to an intervention group, which 
received 1.5 oz. almonds daily for 12 weeks, or to the matched control group, which 
maintained their current diet. No significant differences were found in changes in glucose 
control in response to ingestion of almonds. However, CRP was significantly reduced by 
an average of 36.2% in those that received almonds daily (p = 0.017). Although not 
significant, women randomized to the intervention group appeared to have improvements 
in insulin resistance compared to women with no dietary change. Results suggest that the 
addition of almonds to the diet may be an effective intervention for managing 
inflammation associated with type 2 diabetes. The addition of almonds to the diet is a low 
cost intervention that is easily implemented into daily lifestyle. Due to the small sample 
size, additional studies are needed to determine the impact and mechanisms of almond 
ingestion in subjects with type 2 diabetes.  
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DEFINITION OF TERMS 
Glycemia: the presence of glucose in whole blood 
Postprandial: the 2-hour period following ingestion of food 
Typical diet: adhering to similar dietary patterns to which one is accustomed with 
minimal variation in macro- and micronutrient content. 
Oxidative stress: imbalance between oxidative radicals and antioxidant species within the 
human body leading to an increased risk for disease and pathology 
Inflammation: immunological reactions resulting from physiological stressors 
Estrogenic activity: having effects of, similar to, or antagonistic to estrogen 
Framingham risk score: a cardiovascular risk scoring system based on the Framingham 
Heart Study used to estimate cardiovascular risk over 10 years  
Hyperglycemia: fasting blood sugar ranges over 126mg/dL or 2-hour post ingestion 
glucose ranges over 145 mg/dL 
MET hours: estimated physical activity intensity multiplied by the duration of physical 
activity to estimate total physical activity performed weekly 
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CHAPTER 1 
INTRODUCTION 
It is estimated that 7.8% of people in the United States, and approximately 135 
million people worldwide, have diagnosed or undiagnosed type 2 diabetes1,2. It is 
conservatively estimated to be the seventh leading cause of death in the U.S1. These 
patients have an increased risk for neuropathy, cardiovascular disease (CVD), poor 
wound healing, periodontal disease, retinopathy, kidney disease, certain cancers, 
gallstone disease and death1,3. The American Diabetes Association cites the total cost of 
diabetes nationwide at $245 billion as of 20123. 
Because of these startling figures, there is an increased need for safe, effective 
and affordable interventions that will help to decrease these risks. Almonds may be an 
excellent functional food for those exposed to the increased risk factors associated with 
type 2 diabetes by lowering risks and improving outcomes1,3. Many current diabetic 
treatments involve uncomfortable or even dangerous side effects, including 
hypoglycemia, weight gain, gastrointestinal disturbances, peripheral edema and potential 
cardiovascular effects4. 
Although mechanisms are not clearly defined, almond intake has been associated 
with decreased total cholesterol, lower concentrations of low-density lipoprotein (LDL) 
cholesterol, a favorable ratio of LDL cholesterol to high-density lipoprotein (HDL) 
cholesterol, plasma apolipoprotein B concentrations, and nonesterified fatty acids – all of 
which are important indicators of cardiovascular risk. Almond intake has also been linked 
to lower concentrations of fasting insulin, fasting glucose and homeostatic model 
assessment of insulin resistance (HOMA-IR) 2. 
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Almonds are a good source of many nutrients, including vitamin E, riboflavin, 
niacin, manganese, calcium, magnesium and zinc. A single serving contains 
approximately 3 grams dietary fiber, 6 grams protein, and an average of 25.01 mg 
flavonoids. Arginine, fiber, monounsaturated and polyunsaturated fatty acids, vitamin E, 
and phenolic acids, have all been suggested as bioactive agents underlying the ability of 
almonds to produce cardioprotective effects, however the amounts of these substances 
vary by almond variety5. 
Historically, men and women have starkly different degrees of risk for diabetes 
and its associated complications throughout their individual life cycles. For example, 
when compared to men, women typically have some protection from heart disease prior 
to menopause in spite of other known risk factors including obesity and smoking. 
However, in women with diabetes and women with decreased estrogen status, this 
protection is removed. Lundberg et al. described the relative risk for CVD in men with 
diabetes to be 2.9, while the relative risk for women with diabetes was 5.0 and women 
were approximately 1.75 times more likely to die from a myocardial infarction than 
men6. Moreover, Homko et al. found that total cholesterol, LDL cholesterol and blood 
pressure were significantly higher among women with diabetes than men with diabetes, 
even though Framingham risk scores and treatments were not statistically different 
between the groups. Additionally, women tend to have higher prevalence and more 
pronounced impaired glucose tolerance than men, whereas men have higher rates of 
impaired fasting glucose. Post-challenge hyperglycemia is present in 72% of diabetic 
women, but only in 48% of diabetic men and post glucose challenge hyperglycemia is a 
better predictor of cardiovascular disease in women than in men7.  
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Additionally, Inflammation and triglyceride concentrations predict increased 
cardiovascular risk and metabolic syndrome better in women than in men. Premenopausal 
women have lower rates of hypertension than men matched by age, yet postmenopausal 
women have higher rates of hypertension than men their same age.  
In addition to having different degrees of disease risk, studies have shown that 
men and women may respond differentially to various interventions and treatments. 
Women display low salt sensitivity before menopause, but increased sensitivity after 
menopause7. In an intervention trial, hypertensive women with diabetes exhibited a 
significant dose-dependent response to a walking intervention whereas the men did not8. 
These differential responses to treatment are important because identical treatments are 
typically prescribed by doctors and other healthcare professionals when a treatment that 
is effective for one sex is not necessarily effective or may even exacerbate a condition for 
the other sex. In fact, studies have found that women with cardiac risk factors are less 
aggressively evaluated and treated than men9. This may in part be due to the mistaken 
acceptance that women have a higher protection from disease, the lack of research 
describing the different responses between men and women to various treatments, and a 
historical preference for male subjects in intervention trials. 
A potential reason for these sex-related differences may be varying concentrations 
of the sex hormones estrogen and testosterone between the sexes and within different age 
groups. Low estrogen states such as menopause have been linked to disease states 
including cardiovascular disease and type 2 diabetes. Inflammatory and oxidative stress 
markers as well as glucose and insulin are also elevated in postmenopausal women and 
men with genetic estrogen receptor deficiencies or loss of aromatase function (an enzyme 
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necessary for endogenous estrogen synthesis). Studies show that treatment with estrogen 
in women often improves insulin sensitivity and lowers glycemia. This effect appears to 
be most potent in individuals predisposed to oxidative stress10,11. Other studies, however, 
suggest that estrogens may be pro-inflammatory among older populations of women or 
among those who have been hormone-free for longer periods of time12,13.  
These discrepancies may be explained by estrogen’s complicated role in the body. 
Exogenous estrogens differ pharmacokinetically and are more potent, while endogenous 
estrogens exist in several subtypes, which may have altered or collaborative actions14. It 
may also be related to irreversible changes that may occur in the body with extended 
periods of estrogen deficiency. Estrogens function via two estrogen receptor (ER) 
subtypes – alpha and beta. ER-alpha is most commonly expressed in bone, reproductive 
tissues, white adipose tissue and liver, while ER-beta is expressed in ovaries, prostate, 
lungs, gastrointestinal tract, bladder, hematopoietic cells and the central nervous system. 
Polymorphisms in the gene that codes for ER-alpha correlate with cardiovascular disease, 
type 2 diabetes, myocardial infarction, hypertension, and other metabolic disorders11.  
Testosterone deficiency has been linked to renal disease, obesity, cardiovascular 
disease, metabolic syndrome and type 2 diabetes, among others. Additionally, 
hypogonadal subjects with diabetes treated with testosterone replacement therapy have 
exhibited improvements in insulin resistance, fasting glycemia and hemoglobin A1C 
(HbA1C), improved inflammatory cytokine profile, and decreased visceral fat.  
Testosterone has been effectively increased through lifestyle modifications such as 
weight loss and exercise15-17. 
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A handful of studies have examined the effects of almond intakes ranging from 28 
to 113 grams on blood glucose control. The majority of these studies demonstrated 
improvements in blood glucose control in healthy individuals, those with prediabetes and 
those with stable diabetes2,18-21. Cohen and Johnston studied the effects of low-dose 
almonds on HbA1C in subjects with well-controlled diabetes. They demonstrated 
significant decreases in HBA1C over a 12-week period22. Li et al. found that the addition 
of 60 g almonds per day decreased fasting insulin, HOMA-IR and fasting glucose in 
dyslipidemic patients with type 2 diabetes with stable blood glucose prior to study 
initiation2. Wien et al. also reported decreases in fasting insulin, HOMA-IR and HOMA-
B in subjects with prediabetes provided with a standard dietary intervention or the same 
intervention with 20% energy from almonds (about 57 g). However, decreases in HbA1C 
did not reach statistical significance (p = 0.070) 20. 
 In a 3-arm crossover trial involving 13 healthy subjects, Cassady et al. found that 
55 g of almonds increased GLP-1 and decreased insulin concentrations postprandially in 
a dose-response manner related to the amount of mastication the almonds received23. 
Conversely, a free-living study done by Lovejoy et al. did not find a significant 
correlation between almond intake and insulin sensitivity in healthy individuals after 4 
weeks of 100 g almonds per day. However, insulin sensitivity improved modestly for 
women in the study and neared significance (P = 0.09). Moreover, the addition of 
almonds to the diet of 30 subjects with type 2 diabetes in a controlled feeding study did 
not significantly alter glycemia relative to control diets. While subjects from Lovejoy et 
al. were excluded if fasting blood glucose was less than 140 mg/dL or greater than 200 
mg/dL 21, it is difficult to use fasting blood sugar to estimate overall blood glucose 
 6 
control. Josse et al. found that various doses of almonds (30-90 g) added to a high-
carbohydrate meal decreased postprandial glycemia in a dose-response manner for nine 
healthy subjects with normal fasting blood glucose levels19.  
Of these studies, none considered the differential responses to almond ingestion 
between men and women2,18-20. All of these studies except Cohen and Johnston22included 
high almond doses – at least twice the size of a single serving, and only 2 studies had 
greater than 20 participants2,20. All studies appeared to have included only healthy 
subjects or those with well-controlled blood glucose2,18-20,22,23However, this is difficult to 
extrapolate as only Cohen and Johnston, and Wien et al. reported baseline HbA1C for 
subjects with diabetes. Nonetheless, Li et al. reported that their subjects had stable blood 
glucose for the 3 months prior to study enrollment2and subjects from Lovejoy et al. were 
excluded if fasting blood glucose was less than 140 mg/dL or greater than 200 mg/dL21. 
Functional foods like almonds that have significant health benefits such as 
improving blood lipid profiles, lowering blood sugar concentrations and decreasing 
oxidative stress and inflammation, would be invaluable to the diabetic community as a 
safe, effective and inexpensive intervention for improving risk profiles and preventing 
negative outcomes in this population. Additionally, the dose of almonds used in this 
intervention is realistic for implementation in the diabetic population, lending high 
external validity to the study. 
 
Purpose of Study 
The purpose of this study was to examine the effect of almond ingestion versus 
control diets (unchanged dietary patterns) on glycemic, inflammatory, and oxidative 
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stress biomarkers and the differential responses to almond ingestion between men and 
women. 
  
Aims and Hypotheses 
§ Primary Aim:  
To determine the relationship between sex and markers of glucose control, oxidative 
stress and inflammation following 12 weeks of daily almond consumption in individuals 
with type 2 diabetes. 
§ Primary Hypothesis: 
The effect of almond ingestion on blood markers of glucose control, oxidative stress and 
inflammation in subjects with type 2 diabetes will not differ by gender. 
 
Delimitations and Limitations 
Because the population for this study was self-selected there was a potential for 
selection bias. Individuals who volunteered for this study may represent a subset of the 
population and results may not be generalizable to all members of the population in 
question (those with type 2 diabetes). Additionally, the sample size obtained was likely 
too small to detect significant differences between the control and intervention groups. 
Because of the high HbA1c requirement, results are not generalizable to those with an 
HbA1c lower than 6.5. 
Because this study did not include a placebo, I could not control for the placebo 
effect. Participants could not be blinded to their study condition and therefore results may 
reflect participant bias. In addition, this study was not able to identify all components of 
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almonds that may exert positive antiglycemic, anti-inflammatory and antioxidant effects. 
It is assumed that subjects adhered to the study protocol. 
However, because of strict controls and exclusion criteria, the data obtained from 
this trial may have high internal validity. The intervention allows for high external 
validity because it was implemented on an outpatient basis, using real life scenarios and 
is therefore very generalizable to subjects similar to those used in this study. 
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CHAPTER 2 
REVIEW OF LITERATURE 
Type 2 Diabetes 
Carbohydrate Metabolism 
 Carbohydrates include simple sugars such as the disaccharides lactose and sucrose 
and monosaccharides such as glucose and galactose, as well as complex carbohydrates 
such as fiber, amylose and glycogen. They are necessary for energy in certain cells 
including red blood cells and testicular cells, and are the preferred fuel source for 
virtually all cells in the body24. Carbohydrates are broken down primarily in the small 
intestine, though some breakdown of alpha-1,4 bonds occurs in the mouth as well. In the 
stomach, S cells from the duodenum release secretin, a hormone that stimulates the 
pancreas to release bicarbonate and create a pH in which sugar enzymes can work 
effectively. K cells in the duodenum and jejunum release glucose-dependent 
insulinotropic peptide, which stimulates insulin secretion into the blood in preparation for 
the glucose that will soon be entering circulation. The pancreas releases pancreatic alpha-
amylase, which breaks down a majority of carbohydrates into small pieces, after which 
brush border enzymes are released to break down disaccharides. These enzymes include 
lactase, maltase and the sucrase-isomaltase complex24. 
 Mono- and disaccharides then enter enterocytes using sodium-glucose 
cotransporter 1 or carrier-mediated glucose transporter (GLUT)5. They then enter blood 
circulation via GLUT2 or passive diffusion across the basolateral membrane. Glucose is 
then transported to the liver or to various cells for energy using GLUT 1, 2, or 4 
transporters. At this point, sugars undergo glycolysis to produce ATP for energy, or 
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glycogen synthesis (primarily in myocytes) to store sugars as glycogen for later use. 
GLUT4 is activated by insulin and muscle contractions, and mediates glucose uptake into 
adipose and muscle cells24-26. 
 
Pathophysiology of Type 2 Diabetes and Glucoregulation 
 The exact etiology of type 2 diabetes is not entirely clear. Type 2 diabetes appears 
to be the result of a complex interaction between key inherited and environmental factors 
including hormone imbalance, neurotransmitter dysfunction, genes, body weight, 
increased glucose reabsorption in the kidneys, diet, exercise and lifestyle. Overweight 
and obesity are heavily correlated with the development of insulin resistance and 
impaired glucose tolerance. Overweight and obesity increase leptin, reduce adiponectin 
and increase glucagon concentrations, leading to an imbalance of these hormones. They 
also lead to increased inflammatory cytokine concentrations of tumor necrosis 
factor(TNF)-alpha and interleukin(IL)-6, suppress cytokine signaling and reduce other 
inflammatory signals. Overweight and obesity cause a consequent increase in non-
esterified fatty acid release increasing cellular concentrations of diacylglycerol and fatty 
acyl-CoA, which in turn decrease insulin postreceptor signaling. Abnormalities in 
glucagon-like peptide-1 (GLP-1), hyperglucagonemia and increases in other counter-
regulatory hormones may also contribute to insulin resistance, reduced insulin secretion 
and hyperglycemia4.  
Type 2 diabetes develops when GLUT4 transporters become unresponsive to 
insulin signaling. When beta cells are unable to compensate for the reduced GLUT4 
sensitivity to insulin by secreting more insulin, type 2 diabetes develops. This decline in 
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beta cell function appears to be related to glucotoxicity, lipotoxicity, oxidative stress, 
inflammation and amyloid formation created from a chronic state of hyperglycemia and 
hyperinsulinemia. Additionally, pancreatic alpha cell function declines in many cases of 
type 2 diabetes resulting in increased glucagon secretion that not only promotes further 
hyperglycemia, but may also reduce prandial GLP-1 secretion4. 
Studies suggest that glucose excursion determines the degree of oxidative damage 
measured by isoprostane production better than HbA1C. Greater postprandial 
hyperglycemia is linked to greater oxidative damage. Hyperglycemia is also associated 
with increased production of nitrotyrosine, a marker of oxidative stress18. 
 
Mortality and Morbidity 
Those with type 2 diabetes suffer from increased risk of cardiovascular disease, 
kidney failure, retinopathy, poor wound healing, periodontal disease, gallstone disease, 
certain cancers and death1. Cardiovascular disease contributes to a 75% mortality rate in 
those with type 2 diabetes. This is linked to hyperglycemia, dyslipidemia, hypertension, 
inflammation and oxidative stress – all risk factors that are increased in type 2 diabetes. 
Glucose reduction to sorbitol, glycation end products, impaired antioxidant defenses, 
compromised mitochondrial function and activated NADPH oxidase may all contribute to 
increased oxidative stress in subjects with type 2 diabetes27. Li et al. found that subjects 
with Type 2 Diabetes have higher cardiovascular risk than subjects without the disease 
even when blood glucose is under control2. However, blood glucose control significantly 
reduces risk in those with type 2 diabetes. Blood glucose control can help to improve the 
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lipid profile, decrease blood pressure and reduce inflammation and oxidative stress via 
the pathways mentioned above, as well as through mechanisms yet undefined27. 
 
Oxidative Stress & Inflammation 
Oxidative stress leads to hypertension, cognitive impairment and increased 
inflammation29. Additionally, markers of inflammation such as C-reactive protein (CRP), 
IL-6 and TNF-alpha have been associated with diabetes pathogenesis and development, 
increasing the risk for developing type 2 diabetes in women by an average of 64%30. 
Oxidative stress is caused by reactive oxygen species such as peroxides. As 
mentioned, stable biomarkers of oxidative stress include isoprostanes and nitrotyrosine. 
CRP, IL-6, and TNF-alpha are markers of inflammation. NO is a major endothelium-
derived vasodilator. Increased scavenging of NO by O2- due to oxidative stress 
diminishes the effects of NO. This exacerbates oxidative stress and inflammation 
characteristic of diabetes and causes hypertension. NO produces anti-oxidant, anti-
inflammatory and anti-apoptotic effects in the endothelium28. 
Disulfide bonds are present in thiol-containing molecules such as cysteine, 
methionine and glutathione. These are an expendable source of plasma antioxidants and 
are preferentially consumed in the presence of free radicals. Reduction in protein thiol 
concentration is therefore an additional marker of oxidative stress18. 
 
Oxidative Stress and Inflammation Caused by Diabetic States 
 Hyperglycemia in diabetes creates oxidative stress in vascular endothelium and 
leads to inflammation. In the endothelium, hyperglycemia generates reactive oxygen 
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species such as superoxide (O2-). Superoxide reacts with nitric oxide (NO) to produce 
peroxynitrite (ONOO-). ONOO- is extremely reactive, producing proinflammatory 
posttranslational modifications of cellular proteins such as nitrotyrosine. Nitrotyrosine is 
a marker of nitrative stress and a surrogate marker of ONOO- concentrations. 
Nitrotyrosine can in turn produce isoprostanes which are more stable downstream 
markers of ONOO- concentrations. The products resulting from this modification have 
been linked to enhanced expression of inflammatory molecules, cell death and impaired 
endothelial function28. Cardiovascular disease accounts for more than 70% of morbidity 
and mortality among individuals with type 2 diabetes2. 
 
Almonds 
Chemical Composition 
 Almonds contain many components that are known to have beneficial effects in 
both human and animal models of diabetes and cardiovascular disease. These compounds 
include dietary fiber, magnesium, arginine, plant sterols, polyphenols, copper and many 
others2. 
Almonds also have high levels of mono-unsaturated fatty acids (MUFAs). 
MUFAs may enhance the secretion of GLP-1, a gut hormone known to increase insulin 
secretion in response to glucose intake, promote insulin sensitivity and decrease food 
intake20. Oleic acid in particular might have a beneficial effect on body fat, a risk factor 
for type 2 diabetes and cardiovascular disease, by enhancing mitochondrial fatty acid 
oxidation and thermogenesis by means of up-regulating uncoupling protein genes2. 
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A single 1-ounce serving contains approximately 3.3 grams insoluble fiber, 6 
grams protein, an average of 25.01 mg flavonoids, and 8.9 mg phytosterols. Almonds 
have also been reported to contain significant amounts of other phytochemicals including 
phytates, lignans, sphingolipids, proanthocyanins, and polyphenols19,31.  Phytosterols 
have been linked with lower cholesterol levels and polyphenols show ferric-reducing 
antioxidant power. In addition, almonds have approximately 30 different antioxidants in 
their skin alone, including catechin, epicatechin, isohamnetin, quercetin, kampferol18, and 
alpha-tocopherol (vitamin E) 2. The antioxidant capacity of almonds may help to reduce 
oxidative stress caused by diabeters. Phytates and phenolics have been linked to lower 
postprandial glycemia in vivo and reduced amylolytic digestion (enzymatic starch 
breakdown to sugar) in vitro. Phytates bind to calcium, which is a necessary cofactor for 
amylase activity, and phenolics may bind directly to amylase thereby inhibiting its 
activity. Studies have also demonstrated that insoluble fiber lowers hyperinsulinemia, 
improves glycemic control and lowers plasma lipid concentrations in subjects with type 2 
diabetes19. Arginine, monounsaturated and polyunsaturated fat, and vitamin E, have all 
been suggested as bioactive agents underlying the ability of almonds to produce 
cardioprotective effects, however the amount of these substances varies by variety5. 
 As much as 20% of the energy from almonds is typically lost in the stool. The 
parenchymal cell wall of almonds is resistant to microbial and enzymatic breakdown in 
the gastrointestinal tract. Therefore, liberation of almond lipids for digestion is dependent 
upon the mechanical disruption that occurs with mastication. A study by Cassady et al. 
found that almonds exert effects on fullness, fecal fat losses, and hormone responses. 
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These effects were highly correlated with and dose dependent of the number of chews 
subjects took23. 
 
Potential Health Benefits Exerted by Almonds for Type 2 Diabetes 
 Many studies have suggested a benefit for nut consumption in both healthy and 
unhealthy populations. Epidemiological data from the Nurses’ health Study indicate that 
women who consumed nuts at least 5 times per week had a 29% reduced risk of diabetes 
compared to those who never or almost never ate nuts32. 
Josse et al. found that almonds added to a high carb meal (white bread) decreased 
postprandial glycemia in a dose-response manner for 9 healthy non-diabetic subjects with 
normal fasting blood glucose levels. The authors hypothesized that this was due to the 
ability of almonds to decrease glucose absorption and slow gastric emptying rate when 
ingested with the meal, rather than affecting mechanisms for long-term glucose control19. 
Li et al. found that the addition of 60 g almonds per day for 4 weeks to prepared meals 
decreased fasting insulin, HOMA-IR and glucose by 4.1%, 9.2% and 0.8%, respectively 
in 20 dyslipidemic patients with type 2 diabetes (p = 0.0238, 0.0184, 0.0039). Although 
glucose concentrations were not lowered to the unimpaired range, reductions of this 
magnitude may still be clinically significant. The intervention also lowered body fat by 
0.8% and improved the lipid profiles of these patients, lowering total cholesterol and 
LDL cholesterol and raising HDL cholesterol over the 12-week intervention period2.  
Similar results were found by Wien et al. in a study involving 65 subjects with 
prediabetes. Subjects were provided instructed to follow a standard ADA diet plan, or the 
same diet plan with 20% of energy from almonds, averaging approximately 57 g daily for 
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16 weeks. Results showed improvements in blood lipids, fasting insulin, HOMA-IR and 
HOMA-beta. However, reductions in HbA1C were not greater than those in the control 
group, which were not statistically significant (p = 0.070) 20.  
 In a 3-arm crossover trial involving 13 healthy subjects, Cassady et al. found that 
55 g of almonds increased GLP-1 and decreased insulin concentrations postprandially in 
a dose-response manner relative to the amount of mastication each subject performed on 
the almonds23.  
 Conversely, a free-living study done by Lovejoy et al. did not find a significant 
correlation between almond intake and insulin sensitivity in healthy individuals after 4 
weeks of 100 g almonds per day. However, insulin sensitivity improved modestly for 
women in the study and neared significance (p = 0.09). Moreover, the addition of 
almonds to the diet of 30 subjects with type 2 diabetes in a related controlled feeding trial 
did not significantly alter glycemia relative to control diets. They also found statistically 
significant increases in body weight of 0.9 kilograms in men, which may have masked or 
diminished any changes in insulin sensitivity. Additionally, subjects from Lovejoy et al. 
were excluded if fasting blood glucose was less than 140 mg/dL or greater than 200 
mg/dL21. As previous studies have shown that almonds may affect blood glucose control 
by reducing postprandial glucose18,19,22, it is likely that fasting blood sugar in these ranges 
is indicative that this particular population may not have responded well to a dietary 
intervention. Both studies revealed that almond consumption had beneficial effects on 
lipid values in both studies, improving all major types of cholesterol, with the most 
significant changes being an increased HDL cholesterol21. 
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 Cohen and Johnston reported similar reductions in postprandial glycemia of 30% 
following almond ingestion prior to a mixed meal among subjects with type 2 diabetes, 
but no reduction in postprandial glycemia among healthy subjects. In a separate pilot 
study with 13 subjects with type 2 diabetes, they also reported an additional significant 
reduction of 4% for HbA1C and BMI in subjects in the almond group compared to a 1% 
increase in HbA1C and no change in body mass index (BMI) for the control group22. 
 
Health Benefits on Oxidative Stress and Inflammation 
In addition to lowering postprandial serum insulin and glucose responses to bread, 
the addition of almonds to a standard meal also reduced oxidative damage as measured 
by increases in serum thiol concentrations18 and reduced DNA damage as measured by 
urinary 8-oxo-7,8-dihydro-2’-deoxyguanosine, even among smokers. Reductions in 
urinary malondialdehyde, a marker of lipid peroxidation, and higher superoxide 
dismutase and glutathione peroxidase activity have also been observed with almond 
intake, suggesting that almonds confer antioxidant benefits as well31. 
Rajaram et al. concluded that almond ingestion at 10% or 20% of total energy 
intake was able to reduce CRP by 4.5-9% in healthy subjects compared to the control. 
However they observed no change in IL-633. A crossover trial with varying supplemental 
doses of almonds (37-78g) and control supplement (muffin) found no difference between 
baseline and 4-week intervention period measures of CRP in 27 hyperlipidemic 
subjects34. 
Liu et al. compared a control National Cholesterol Education Program (NCEP) 
step II diet to a 56 g daily almond intervention diet for four weeks in subjects with type 2 
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diabetes using a crossover randomized control design. They found that compared to the 
control diet, IL-6 and CRP were significantly reduced by medians of 10.3%, each27. 
 
Metabolic Sex Differences & Treatment Responsiveness 
 Considering metabolic differences between men and women is paramount to 
designing treatment interventions for the different genders at each stage of life. It has 
been suggested that treatment and diagnosis of women’s heart disease is followed less 
strictly by physicians. Additionally, women are often underrepresented in clinical trials 
regarding heart disease and gender-specific analyses are not always present in older large 
trials35.  
Differing fat deposition patterns between men and women may also affect 
responses to insulin, adrenaline, norepinephrine and sex hormones7. Women have a 
greater percentage of body fat even though they typically have smaller energy intake per 
kilogram lean body mass than men and preferentially use fat as fuel during exercise. 
Women also have more efficient fat storage during sedentary time, especially 
postprandially, while men tend to oxidize a greater percentage of ingested fat than 
women. Estrogen is thought to be at least partially responsible for this difference in fat 
metabolism. Studies suggest that estrogen may influence the hepatic processing of dietary 
fats14.  
Treatment responses to interventions also frequently differ between men and 
women. In one study, six months of flax lignin supplementation decreased metabolic 
syndrome composite scores in men, but not in women29. 
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In addition to estrogen and testosterone, other hormone levels vary between men 
and women. Leptin is higher per kilogram body weight in women than in men. Leptin is 
an important appetite-regulating hormone produced in adipocytes and has been shown to 
be inhibited by androgens and promoted by estrogens. Estrogens may also alter 
hypothalamic sensitivity to leptin by binding to estrogen receptors found in the 
hypothalamus. However, this relationship is unclear because leptin does not appear to be 
affected in menopause or by estrogen replacement therapy14. 
Presentation of diabetes differs substantially between men and women. Men with 
diabetes show impaired fasting glucose more frequently than women, and impaired 
glucose tolerance presents more often in women than in men. In fact, post-challenge 
hyperglycemia is the only symptom of diabetes in 72% of women, but only 48% of men. 
Using fasting or postprandial glucose exclusively as criterion for diabetes screening and 
diagnosis would miss metabolic abnormalities in a substantial subset of the population7. 
Women typically enjoy relative cardioprotection prior to menopause compared to 
men. However, it appears that this protection disappears in those with diabetes as acute 
myocardial infarction incidence is three times higher for diabetic men than men without 
diabetes, but five times higher for diabetic women compared to nondiabetic women. 
Additionally, mortality from acute myocardial infarction was more than seven times 
greater among females with diabetes, and four times greater among men than among 
nondiabetic individuals6. Inflammation increases cardiovascular risk to a greater extent in 
women than in men7. This may be due to the effects that diabetes may have on estrogen 
action, particularly at the estrogen receptors.  
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A steep increase in myocardial infarction is observed in women ages 55-64 years 
when compared to the previous decade of life. This may be due to an interaction between 
diabetes and postmenopausal estrogen loss that adds a particularly high risk for these 
subjects. Prior to this, the 35-44 year age group displays the highest incidence and rate of 
recurrent acute myocardial infarctions among diabetic women. This early increased risk 
may be due to a mean onset age for diabetes of 11.8 years, which is significantly younger 
than the mean onset age of 24.7 years in men6. 
 
Estrogen 
 Estrogen may be an integral cause of differences in chronic disease development, 
presentation and treatment effectiveness between men and women. In heart failure and 
hypertrophy, estrogen receptors within the heart are upregulated, possibly modulating the 
progression of the disease35. Estrogens are involved in the regulation of insulin 
sensitivity, energy balance, blood pressure and body composition, impacting appetite, 
insulin release, glucose transport in hepatocytes and skeletal myocytes, adipocyte 
differentiation, and vascular tone and structure36. 
Endogenous estrogens exist in three subtypes: estrone, estriol and estradiol. Each 
has slightly different actions that may be antagonistic or synergistic. Estradiol is the most 
potent of these and has the highest binding affinity for both alpha and beta estrogen 
receptors, but it does not exist in the highest concentrations. Relative concentrations of 
each subtype vary by life cycle stage. Each of these estrogens is likely to produce 
differential activation of the ERs37. 
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 ERs exist in two different isoforms: alpha and beta. ER-alpha is expressed 
primarily in the uterus, pituitary, kidney and adrenal gland38 and appears to influence 
aromatase expression, adiposity and hepatic adiposity39. ER-alpha is also involved in the 
estrogen stimulation of NO synthase40. ER-beta is expressed primarily in prostate, ovary, 
bladder and lung cells. The two isoforms are almost identical, differing only in the 
change from a serine to a methionine in ER-beta38. The function of the beta receptor is 
uncertain as no overt phenotype has been described from studies on animals lacking this 
receptor39. 
 
Testosterone 
Associations of Testosterone with Type 2 Diabetes 
 Hypogonadism, characterized by low testosterone levels, is associated with 
several conditions including obesity, cardiovascular disease and mortality, liver cirrhosis, 
chronic renal failure, metabolic syndrome and type 2 diabetes. It is widely under-
recognized and under-diagnosed and particularly prevalent in type 2 diabetes. Lower 
testosterone levels increase risk of cardiovascular disease and mortality; and testosterone 
concentrations are associated with decreases in insulin sensitivity, dyslipidemia and 
increased body fat41.  
Testosterone treatment of subjects with type 2 diabetes has been associated with 
improved insulin sensitivity. One study reported that a two-week withdrawal of 
testosterone replacement therapy resulted in impaired insulin sensitivity without affecting 
body composition. Other studies involving type 2 diabetic subjects, investigated the 
effects of testosterone therapy and found that testosterone undecanoate improved fasting 
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glycemia, postprandial glycemia, insulin sensitivity, mean HbA1C, total cholesterol, fat 
mass and reduced visceral adiposity17. Additionally, treatment of isolated stem cells with 
testosterone increased their development into myocytes rather than adipocytes while 
testosterone deficiency had the opposite effect41. 
The hypogonadal obesity cycle hypothesis suggests that these associations may be 
self-perpetuating. Excess adipocytes release aromatase, which metabolizes testosterone to 
17beta-estradiol. Decreased testosterone levels then allow increased lipoprotein lipase 
activity, which in turn causes increased fatty acid uptake and storage by adipocytes. The 
increased fat mass leads to increased insulin resistance and even greater breakdown of 
testosterone. A second hypothesis, the hypogonadal obesity adipocytokine hypothesis 
suggests that a normal hypothalamic-pituitary-testicular response to hypotestosteronemia 
is inhibited by 17beta-estradiol, leptin and the adipocytokines IL-6 and TNF alpha41. 
 
Links between Testosterone and Inflammation and Oxidative Stress 
 Levels of IL-6 and CRP have been significantly inversely correlated with total 
and bioavailable amounts of plasma testosterone concentrations, suggesting that low 
testosterone is linked to inflammation. Additionally, testosterone replacement therapy in 
hypogonadal individuals resulted in the ex vivo reduction of proinflammatory cytokines. 
Treatment with testosterone prior to intracoronary stenting procedures has also been 
shown to reduce the concentrations of inflammatory markers such as IL-6 and CRP41. 
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Conclusion 
 Diabetes prevalence is increasing rapidly throughout the United States and in 
other parts of the world with high rates of mortality and morbidity. Relative risk, 
presentation and treatment outcomes for diabetes and its related complications differ 
markedly between men and women. These differences likely relate to differing sex 
hormone concentrations, specifically estrogen and testosterone. Conditions of low 
estrogen or low testosterone are related to type 2 diabetes pathology, oxidative stress and 
inflammation. 
 Almonds are a promising treatment option for subjects with type 2 diabetes, but 
treatment results may differ between the sexes. A limited number of studies suggest that 
almonds may improve glucose control, insulin sensitivity, and markers of oxidative stress 
and inflammation. The mechanism for their beneficial actions may be any number of 
favorable compounds they contain, namely insoluble fiber, flavonoids, phytates, arginine, 
monounsaturated and polyunsaturated fatty acids, and phenolic acids. 
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CHAPTER 3 
MATERIALS AND METHODS 
Subjects 
 The enrollment goal for this study was fifty subjects between the ages of 25 and 
75 years of age who had been previously diagnosed with type 2 diabetes mellitus at least 
6 months prior to study enrollment. The n for this study was determined by collaboration 
with colleagues in addition to the use of sample size calculation software developed by 
David Shoenfield of Harvard University. We estimated a standard deviation in HbA1C of 
1.01 based on the mean of a compilation of 43 studies found in a meta-analysis by 
Giugliano et al. 42 and a difference between means of 0.63 based upon an average 
reduction in HbA1c from two similar dietary interventions20,43, using a significance level 
of P = 0.05 and power of 0.8. This calculation yielded n = 84. However, due to the 
unattainability of this number and agreement with the California Almond Board, along 
with consultation with experts, we determined to recruit an n of 50. Participants were 
recruited from college campuses, diabetes support groups and treatment centers, 
healthcare centers, community centers and shopping areas in the Phoenix metropolitan 
area. One hundred fifty-five individuals responded to our pre-screening survey 
administered online through SurveyMonkey over the course of a 9 month enrollment 
period. Of these, 82 met inclusion criteria and were screened for study eligibility. Of the 
82 screened, 56 were excluded due to failure to meet exclusion criteria and the remaining 
26 were enrolled in the study. Three subjects withdrew before study completion, leaving 
23 subjects that were included in all analyses. 
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 Inclusion criteria for participation in the study were that subjects could not be 
prescribed insulin, must not have a history of tree nut allergy, and must not be pregnant 
or lactating. Exclusion criteria were HbA1C less than 6.50%, and a dietary intake of 
greater than 12% monounsaturated fatty acids. Prescription medication use was required 
to be consistent throughout the duration of the study with no intention of attempting 
weight loss or gain or plans to change eating habits or physical activity. 
 
Study Protocol 
 Participants were asked to meet with researchers on four separate occasions 
during the course of the study. The first visit was a screening designed to determine 
whether participants met certain exclusion criteria, including HbA1c greater than 6.50%, 
to provide participants with study information, and to obtain informed consent. Weight, 
height, waist circumference, and body mass index (BMI) were measured. Body 
composition was measured using bioelectrical impedance analysis. HbA1C and blood 
pressure were also assessed and a monounsaturated fatty acid food frequency 
questionnaire and medical questionnaire were administered. Participants were instructed 
to complete a 3-day diet record prior to the second, third and final appointments and to 
restrict intake of all tree nuts to less than 2 servings per week, except for the almonds 
provided. Participants were then instructed to come in the following week and every 6 
weeks thereafter for the duration of the 12-week study, for a total of 4 visits. Participants 
were to fast overnight (for at least 8 hours) prior to visits 2, 3 and 4. At each visit fasting 
blood was drawn. Aliquots of plasma were stored at -80°C for the analyses of glycemia, 
plasma insulin, oxidative stress and inflammatory markers at the conclusion of the study. 
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HbA1C, blood pressure and all anthropometric measures were reassessed. Analysis of the 
three-day dietary recall and physical activity assessment was also performed (See Figure 
1).  
 Participants were stratified by age, BMI, HbA1C, duration of diabetes, and gender. 
They were then randomly assigned to either the intervention group or the control group. 
The intervention group received 60 ounces of almonds and was instructed to consume 1.5 
ounces (43 g) 5 to 7 days per week for the 12-week trial period. The control group was 
instructed to maintain their current diet and physical activity levels. 
 
Figure 1 
Study Outline
 
 
Laboratory Analysis 
 HbA1C was measured using capillary electrophoresis (COBAS Analyzer, Roche, 
Indianapolis, ID). It is a measure of the percent hemoglobin in red blood cells with 
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glucose attached and an indirect measure of long-term blood glucose control. Poor blood 
glucose control is associated with cardiovascular disease, nephropathy, retinopathy and 
other disease conditions. Because red blood cells have an average 120-day life cycle, it is 
necessary to measure HbA1C throughout the 12-week study duration. However, glycated 
hemoglobin is believed to be most representative of the previous 2 to 4 weeks44. Fasting 
serum insulin and glucose concentrations were also measured by enzyme immunoassay 
and COBAS Analyzer, respectively. HOMA-IR was calculated as (insulin µU/mL x 
glucose mM)/22.5.  
 4-hydroxynonenal (4-HNE) is a marker of oxidative stress. 4-HNE may be 
involved in the development of diabetes, atherogenesis, cancer and other disease 
conditions45. This was measured using a commercially available kit according to the 
manufacturer’s instructions.  
Tumor necrosis factor-alpha (TNF-alpha) and interleukin-6 (IL-6) are important 
inflammatory cytokines. TNF-alpha induces fever, controls immune cells by apoptosis, 
triggers IL-1 and IL-6 production, induces cachexia, and inhibits tumor growth and viral 
replication. Irregular concentrations are linked to Alzheimer’s disease, cancer, irritable 
bowel disease, depression, asthma, type 2 diabetes, arthritis, cancer and Crohn’s 
disease30. IL-6 increases acutely following infection, trauma, and exercise. 
Concentrations are increased during chronic inflammatory conditions such as obesity, 
insulin resistance, inflammatory bowel disease, arthritis and others. Additionally, IL-6 
contributes to atherosclerotic plaque development and destabilization. IL-6 can serve as 
both a pro- and anti-inflammatory cytokine as in exercise and its modulation of bone 
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resorption46. Plasma concentrations of TNF-alpha and IL-6 were quantified using 
commercially available kits according to the manufacturer’s protocols.   
A lipid panel was also performed using nuclear magnetic resonance 
spectrophotometry and quantitative enzymatic testing. Because almonds are a rich source 
of tocopherols, serum tocopherol was measured using HPLC as they have potent 
antioxidant properties; they were also used to verify compliance with the study protocol. 
 
Statistical Analyses 
 The data was analyzed using SPSS Statistical software. Data were analyzed once 
including all data points, and a second time excluding all subject data with baseline 
HbA1C greater than 9.00%. Two-way repeated measures ANOVA was used to compare 
men and women in all biological parameters including HbA1C, insulin, glucose, HOMA-
IR, anthropometric measures, lipids, inflammatory markers, oxidative stress markers, and 
tocopherols. Two-way repeated measures ANOVA was used to compare compliance, 
dietary intake, and all other measures. Reported baseline physical activity was used to 
calculate estimated MET hours per week. Independent T-tests were used to compare 
HbA1C concentrations, and changes in all variables between men and women subjects. 
Mann-Whitney U Tests were used to determine statistical significance of all data. 
Pearson correlation was used to identify possible covariates that may have confounded 
data including physical activity, age, baseline anthropometrics, and baseline variables of 
glucose control, oxidative stress and inflammation. Correlations with a p <0.05 were 
considered to be significant confounding variables. Mean, median, mode and standard 
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deviation were measured for all variables. For all comparisons, P<0.05 were considered 
statistically significant. 
The study was approved by the Arizona State University Institutional Review 
Board (IRB) that oversees all studies involving human subjects. Informed consent was 
administered at the first study visit when subjects were notified of potential risks and 
benefits for participating in the study. Potential risks included bruising or a feeling of 
faintness during blood draws, or an allergic reaction to the almonds. There were no 
conflicts of interest involved in this study and confidentiality was maintained throughout 
the study by assigning each subject an ID number and keeping consent forms separate 
from data. 
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CHAPTER 4 
 
RESULTS 
Descriptive characteristics 
TABLE 1. Baseline Characteristics of Subjects1 
 Women 
(n = 15) 
Men 
(n = 9) 
p-value 
Age (y) 56.3 ± 8.61 59.56 ± 4.0 0.4552 
BMI (kg/m2) 35.87 ± 9.60 34.00 ± 6.2 0.835 
HbA1c (%) 7.3 ± 1.1 7.1 ± 0.7 0.529 
Fasting insulin (mg/dL) 27.92 ± 14.4 35.91 ± 32.7 0.713 
Fasting glucose (mg/dL) 152.4 ± 42.1 160.7 ± 34.6 0.548 
METs 177.8 ± 338.1 197.5 ± 311.6 0.172 
1Data are mean ± SD; n = 23 
2P values were obtained from independent samples Mann-Whitney Test 
 
 As shown in table 1, the age of participants ranged from 44 to 70 years with a 
mean age of 57.5. The average body mass index (BMI) for subjects was 35.2 kg/m2. 
Subjects had an average HbA1C of 7.3%, and a fasting insulin and fasting glucose of 
31.187 mg/dL and 155.77 mg/dL, respectively. Mean METs per week performed by 
participants was 185.0. 
 BMI was significantly correlated to IL-6 (r = 0.566, p = 0.005) and CRP (r 
=0.629, p = 0.002) at baseline. Age and insulin were negatively correlated (r = -0.501, p 
= 0.013). HNE and HbA1c were positively correlated at baseline (r = 0.423, p = 0.044). 
IL-6 and CRP were correlated (r = 0.544, p = 0.009), as were HNE and TNF-alpha (r = -
0.521, p = 0.011). Baseline characteristics were not significantly different between men 
and women p>0.05. 
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Anthropometrics 
 There were no significant differences in BMI, weight, waist circumference, or 
percent body fat in either men or women. However, anthropometric measures tended to 
improve in men in the almond group compared to women, in whom measures tended to 
become worse or remain the same over time. (See tables 2 and 3.) 
 
 
  
 
 
 
 
1P values were obtained from independent samples Mann-Whitney Test 
 
1P values were obtained from independent samples Mann-Whitney Test 
  
 
TABLE 2. Mean Change in BMI, Weight, Waist Circumference and Percent 
Body Fat in Men  
  0 Weeks 12 Weeks Change p-value1 
BMI (kg/m2) ALM = 5 34.7 32.3 -2.4 0.803 
 CON = 4 33.2 32.8 -0.4  
Weight (lbs.) ALM 239.93 237.49 -2.44 0.806 
 CON 215.86 214.36 -1.50  
Waist (in.) ALM 46.3 45.8 -0.5 0.325 
 CON 41.3 41.9 -.6  
Body Fat (%) ALM 34.4 38.1 3.7 0.327 
 CON 34.0 33.2 -0.8  
TABLE 3. Mean Change in BMI, Weight, Waist Circumference and Percent 
Body Fat in Women 
  0 Weeks 12 Weeks Change p-value1 
BMI (kg/m2) ALM = 6 36.9 37.1 0.2 0.474 
 CON = 8 34.7 34.2 -0.68  
Weight (lbs.) ALM 213.84 214.64 0.80 0.604 
 CON 202.48 198.54 -3.95  
Waist (in.) ALM 44.3 44.9 0.6 0.135 
 CON 43.7 42.7 -.09  
Body Fat (%) ALM 45.9 45.3 -0.6 0.948 
 CON 43.9 42.9 -1.0  
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 Energy and nutrient intake was estimated using 3-day food records collected at 
each fasting blood draw. Food Processor software was used to estimate intake and 
nutrient distribution and standardized food lists were used for ambiguous food listings. 
Total kcals decreased and macronutrient distribution changed over time in women, but 
not in men (Tables 4 and 5). Total kcals decreased by a net total of 583 kcals between the 
almond and control groups (p = 0.042). Percent energy from carbohydrate decreased by 
15.14% while percent energy from protein increased by 2.43% (p = 0.017 and 0.062, 
respectively). Changes in energy and calorie distribution were not statistically different 
between the control group and the almond group in men. 
 
TABLE 4. Mean Change in Energy and Macronutrient Distribution for Women  
  0 Weeks 12 Weeks Change p-value1 
Energy (kcals) ALM = 6 2205 1520 -686 0.042 
 CON = 8 1645 1541 -103  
Carbohydrate (%) ALM 52.69 37.54 -15.14 0.017 
 CON 43.97 44.71 .74  
Protein (%) ALM 15.09 17.52 2.43 0.062 
 CON 17.20 14.95 -2.25  
Fat (%) ALM 43.29 45.98 2.68 1.000 
 CON 35.73 37.56 1.83  
1P values were obtained from independent samples Mann-Whitney Test 
TABLE 5. Mean Change in Energy and Macronutrient Distribution for Men  
  0 Weeks 12 Weeks Change p-value1 
Energy (kcals) ALM = 5 1839 1916 77 0.827 
 CON = 4 1596 1776 180  
Carbohydrate (%) ALM 37.95 39.45 1.49 0.275 
 CON 36.08 48.62 12.54  
Protein (%) ALM 17.72 22.50 4.78 0.127 
 CON 19.15 17.21 -1.95  
Fat (%) ALM 44.04 38.36 -5.68 0.827 
 CON 42.62 35.33 -7.29  
1P values were obtained from independent samples Mann-Whitney Test 
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Insulin Resistance 
 No significant changes were observed in markers of insulin sensitivity over the 
12-week intervention period in either men or women (see Tables 6-9). Markers of insulin 
resistance more closely neared statistical significance in men compared to women for 
every marker except for HbA1C.  
 
 
 
 
 
 
TABLE 6. Overall Mean and Mean Changes in Markers of Insulin Resistance  
  0 Weeks 12 Weeks Change p-value1 
Glucose ALM = 11 156.8 152.7 -4.1 0.768 
 CON = 12 154.8 161.6 6.8  
Insulin ALM 28.9 30.42 1.53 0.279 
 CON 33.48 35.52 2.04  
A1c ALM 7.4 7.4 0.0 0.510 
 CON 7.4 7.2 -0.2  
HOMA-IR ALM 11.43 11.97 0.54 0.622 
 CON 10.53 15.64 5.1  
1P values were obtained from independent samples Mann-Whitney Test 
TABLE 7. Mean and Mean Changes in Markers of Insulin Resistance in Men  
  0 Weeks 12 Weeks Change p-value1 
Glucose ALM (n = 5) 174.5 150.1 -24.4 0.462 
 CON (n = 4) 143.5 126.9 -16.6  
Insulin ALM 28.02 32.75 4.74 0.142 
 CON 45.77 37.41 -8.37  
A1c ALM 7.2 7 -0.1 0.805 
 CON 7.2 7.1 -0.1  
HOMA-IR ALM 12.16 12.82 -0.66 0.462 
 CON 11.78 11.13 -0.66  
1P values were obtained from independent samples Mann-Whitney Test 
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1P values were obtained from independent samples Mann-Whitney Test 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
TABLE 8. Mean and Mean Changes in Markers of Insulin Resistance in 
Women  
  0 Weeks 12 Weeks Change p-value1 
Glucose ALM = 6 142 154.8 12.8 0.886 
 CON = 8 161.2 181.5 20.3  
Insulin ALM 29.63 28.48 -1.14 0.775 
 CON 26.45 34.43 7.98  
A1c ALM 7.6 7.6 0.1 0.566 
 CON  7.6 7.3 -0.2  
HOMA-IR ALM 10.83 11.27 0.44 0.886 
 CON 9.82 18.21 8.39  
TABLE 9. Change in Markers of Glucose Control, 
Comparison Between Men and Women 
  M F 
Glucose ALM = 11 -24.4 12.8 
 CON = 12 -16.6 20.3 
Insulin ALM 4.74 -1.14 
 CON -8.37 7.98 
A1c ALM -0.1 0.1 
 CON -0.1 -0.2 
HOMA-IR ALM -0.66 0.44 
 CON -0.66 8.39 
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Oxidative Stress and Inflammation 
 There were no significant differences in change in markers of oxidative stress and 
inflammation over the 12-week intervention period (Tables 10-13). However, CRP 
neared significance in the almond group (men and women combined) compared to the 
control group (p = 0.053). When outliers were removed (HbA1C >9.0%), CRP reached 
significance (p = 0.017). 
 
 
TABLE 10. Overall Mean and Mean Changes in Markers of Oxidative 
Stress and Inflammation over 12 Weeks (outliers removed) 
  0 Weeks 12 Weeks Change p-value1 
CRP ALM = 11 4.31 3.11 -1.20 0.017 
 CON = 12 5.68 9.75 4.08  
IL-6 ALM 1.128 1.008 -0.120 0.373 
 CON 1.585 1.749 0.164  
HNE ALM 84.13 81.41 -2.72 0.742 
 CON 102.39 98.60 -3.79  
TNFa ALM 33.76 35.01 1.25 0.767 
 CON 25.81 26.80 1.00  
1P values were obtained from independent samples Mann-Whitney Test 
 
 
 
 
 
TABLE 11. Overall Mean and Mean Changes in Markers of Oxidative 
Stress and Inflammation over 12 Weeks in Men  
  0 Weeks 12 Weeks Change p-value1 
CRP ALM = 5 3.01 1.97 -1.03 0.221 
 CON = 4 1.87 2.07 0.198  
IL-6 ALM 0.795 0.812 0.017 1.000 
 CON 1.468 1.453 -0.015  
HNE ALM 78.19 75.97 -2.23 0.806 
 CON 80.04 78.82 -1.22  
TNFa ALM 32.02 34.13 2.11 0.539 
 CON 32.97 33.61 0.64  
1P values were obtained from independent samples Mann-Whitney Test 
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TABLE 12. Overall Mean and Mean Changes in Markers of Oxidative 
Stress and Inflammation over 12 Weeks in Women (outliers removed) 
  0 Weeks 12 Weeks Change p-value1 
CRP ALM = 6 5.62 4.25 -1.37 0.088 
 CON = 8 7.85 14.14 6.29  
IL-6 ALM 1.461 1.205 -0.256 0.306 
 CON 1.644 1.898 0.254  
HNE ALM 90.06 86.85 -3.20 0.661 
 CON 113.56 108.48 -5.08  
TNF-alpha ALM 35.50 35.90 0.40 1.000 
 CON 22.22 23.4 1.17  
1P values were obtained from independent samples Mann-Whitney Test 
 
 
 
TABLE 13. Change in Markers of Oxidative 
Stress and Inflammation, Comparison of Men 
and Women (outliers removed) 
  M F 
CRP ALM -1.03 -1.37 
 CON 0.198 6.29 
IL-6 ALM 0.017 -0.256 
 CON -0.015 0.254 
HNE ALM -2.23 -3.20 
 CON -1.22 -5.08 
TNF-alpha ALM 2.11 0.40 
  CON 0.64 1.17 
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CHAPTER 5 
DISCUSSION 
 
 No significant difference was observed in markers of glucose control. Changes in 
IL-6, HNE and TNF-alpha also did not reach statistical significance. However, when 
subjects with a baseline HbA1C >9.0% were removed, CRP was reduced by an average of 
1.20 mg/dL (27.8%), which was statistically significant (p = 0.017, both sexes combined; 
see Table 10). CRP is a major biomarker of inflammation. Chronic low-grade 
inflammation has been linked to increased risk for obesity, cancer and atherosclerosis. 
Long-term dietary patterns have been linked to elevations in CRP; however, few 
individual randomized control trials have been able to link specific foods to reductions in 
CRP47. Our results are consistent with the results from other studies demonstrating that 
almond ingestion can effectively reduce CRP concentrations in a variety of 
populations27,33, however not all studies have demonstrated significant differences in 
CRP with almond ingestion34. This is the second study to show that CRP can be reduced 
by almond ingestion in a diabetic population. Therefore, this study demonstrates that a 
simple dietary intervention of consuming 1.5 oz. almonds daily is effective at reducing 
inflammation among those with type 2 diabetes. 
 The ability of almonds to reduce CRP has been attributed to their high MUFA 
content (although previous studies with alternative sources of MUFA have not 
consistently affirmed this mechanism33,48) via a decrease in E-selectin that could lower 
the inflammatory response, thus reducing CRP33. Magnesium has also been inversely 
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correlated with serum CRP concentrations27,49Arginine, alpha-tocopherol and other 
phytonutrients may also play a role in modifying inflammatory responders27,33. 
 In spite of the significant response of CRP to almond ingestion, suggesting 
decreased inflammation, changes in IL-6 were not statistically significant in this study. 
Mean change data suggested that women in the almond group had average declines in IL-
6 of -0.256 compared to women in the control group, which experienced average 
increases in IL-6 of 0.254 (p = 0.306; see figure 7).  
 Other studies have shown mixed results regarding the response of IL-6 to almond 
ingestion. In similar studies, one study showed that CRP and IL-6 concomitantly 
decreased with daily almond ingestion27, while another found significant differences only 
in CRP reduction with almond intake33. These discrepancies may have been due in part to 
the small sample size, or lack of internal controls. In the Liu et al. study, all subjects were 
involved in both arms of the study, providing their own controls, a placebo diet was 
provided, and all meals were provided by a metabolic kitchen, decreasing interindividual 
variations in diet and all other individual measures27. However, providing meals to 
subjects would have decreased the generalizability of this study. The inability of this 
study to demonstrate significant changes in IL-6 may also be related to the nature of IL-6. 
IL-6 is subject to diurnal variations and is lower in the morning than it is at night; CRP 
does not exhibit such diurnal variations. CRP is a better predictor of cardiovascular 
disease than IL-6 when morning-extracted blood samples are used, as was the case in this 
trial33.  
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 Women in the intervention group had significant changes in their dietary patterns 
according to 3-day dietary recalls. Total calories decreased over time from an average of 
2520 daily to 2205 (p = 0.042). Additionally, macronutrient composition of the diet 
changed with a decrease in carbohydrate composition from 52.69% to 37.54% compared 
to 43.97% to 44.71% in the control group (p = 0.017) and an increase in dietary 
composition of protein from 15.09% to 17.52% in the almond group and a decrease from 
17.20% to 14.95% in the control group. Dietary changes were not significant for men. 
The decreased caloric intake and improved macronutrient profile observed for women in 
the almond group may be due to the composition of almonds. Almonds are a good source 
of protein and have a satiating quality27, thereby reducing caloric intake. Wien et al. 
showed similar changes in dietary macronutrient composition, with a significant decrease 
in percent calories from carbohydrate. These results were significant in spite of 
concentrated attempts to maintain dietary consistency within subjects throughout the 
study period through the employ of a registered dietitian and double blinding. While 
Wien et al. did not report sex differences in their data, 69% and 79% of almond 
intervention and control subjects, respectively were female20 
 While no change was observed in HbA1c over the intervention period, 
nonsignificant changes were observed for blood glucose and insulin. HOMA-IR 
combines these values to provide a reliable estimate of actual glucose control. All groups 
remained largely unchanged except for women in the control group, in which HOMA-IR 
worsened significantly. In observing individual changes in HOMA-IR, it can be seen that 
4 of the 6 women in the almond group had decreased or unchanged values, whereas 
among men in the almond group, no trend is seen (see Figures 8-11). From this, it was 
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observed that almond ingestion in women may have produced better protections from 
deteriorating blood glucose control while glucose control in men remained largely 
unchanged by almond ingestion. This may be at least partly due to the observation that 
women with type 2 diabetes are more likely to have impaired glucose tolerance when 
presented with a glycemic challenge, while men with type 2 diabetes are more likely to 
exhibit impaired fasting glucose7. If almond ingestion improves glucose control by 
affecting postprandial glucose, the effect would be expected to be more prominent in 
women. 
 
Figure 8.     Figure 9.    
 
Figure 10.     Figure 11. 
 
-­‐2	  0	  
2	  4	  
6	  8	  
10	  
M	   F	  
Change in HOMA-IR 12 Weeks 
ALM	  CON	  
-­‐30	  -­‐20	  
-­‐10	  0	  
10	  20	  
30	  
M	   F	  
Change in Glucose 12 Weeks 
ALM	  CON	  
3.35	   2.86	  5.79	   8.32	  
21.04	   17.37	  11.55	   19.41	  5.12	   5.37	  
18.11	   14.26	  
0	  5	  
10	  15	  
20	  25	  
0	  Weeks	   12	  Weeks	  
HOMA-­‐IR:	  Women,	  Almond	  
18.09	   24.46	  20.15	   19.37	  
6.35	   9.12	  7.87	   4.18	  8.36	   6.97	  0	  10	  
20	  30	  
0	  Weeks	   12	  Weeks	  
HOMA-­‐IR:	  Men,	  Almond	  
 42 
 The lack of significant change in glycemic control observed in this population has 
not been demonstrated in other studies2,18,19,22. This may in part be due to the exclusion 
criteria that may have unintentionally excluded the population that would be most 
sensitive to dietary intervention – those with better glucose control. Subjects with poorly 
controlled diabetes have not been studied in this context before and may be less sensitive 
to dietary interventions, especially those designed to lower postprandial glucose. As 
Monnier et al. points out, average daily plasma glucose is better predicted by postprandial 
plasma glucose than by fasting plasma glucose concentrations among subjects with type 2 
diabetes, whereas in subjects with higher HbA1C, fasting plasma concentrations were a 
better predictor of average daily plasma glucose concentrations50. Previous studies have 
suggested that almonds are able to improve postprandial blood glucose 
concentrations18,19,22, but not fasting glucose concentrations20-22, but only one study has 
demonstrated that almonds may also reduce fasting glucose concentrations2. 
Additionally, this study used a much lower dose of almonds than has been used in 
previous studies2,18,20,21 and was subject to the placebo effect as no placebo was used and 
subject blinding was not possible.  
 This study had excellent controls, which allowed for high external validity. 
However, largely due to restrictive exclusion criteria that required an HbA1C ≥6.50%, the 
goal number of participants were not recruited. This may have contributed to an inability 
of the results to demonstrate statistical significance in the results. Additionally, METs 
and dietary intake, as well as total estimated MUFA intake were measured via subject 
report. Dietary and physical activity may have been misreported. 
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 Previous studies have suggested that almond ingestion may minimize postprandial 
glucose excursions, however this study was unable to demonstrate statistically significant 
improvements in blood glucose control with almond ingestion. Future studies should 
include subjects with a wider range of glucose control including those with diabetes who 
have excellent glucose control and those with prediabetes in order to delineate whether 
only particular diabetic populations may benefit from a dietary intervention that includes 
almonds. Future studies should also aim to include a higher number of subjects with 
diabetes. 
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CHAPTER 6 
CONCLUSION 
 While data is too preliminary to suggest standardized supplementation 
recommendations to regulate blood glucose for individuals with type 2 diabetes, results 
of previous studies in combination with this study suggest that almond supplementation 
may be beneficial in this and other populations for reducing inflammation. It seems clear 
that almond ingestion is beneficial for ameliorating inflammation and improving the lipid 
profile in at risk individuals, as well as in healthy populations. Additional larger-scale 
studies are needed in order to delineate the potential benefits of almond supplementation 
on blood glucose control, oxidative stress and inflammation. Future studies should 
include individuals with greater variety in blood glucose control and seek to determine 
whether this dietary intervention could have varying impacts on individuals with greater 
or lesser blood glucose control than those studied in this study.  
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BENEFIT OF PLANT FAT FOR REDUCING CARDIOVASCULAR RISK FACTORS IN  
INDIVIDUALS WITH TYPE 2 DIABETES 
 
INTRODUCTON 
The purposes of this form are (1) to provide you with information that may affect your decision as to whether or 
not to participate in this research study, and (2) to record your consent if you choose to be involved in this study. 
 
RESEARCHERS 
Drs. Karen Sweazea and Carol Johnston, Nutrition professors at Arizona State University Downtown Campus, 
and Kristin Ricklefs, a nutrition doctoral student, have requested your participation in a research study. 
 
STUDY PURPOSE 
The purpose of the research is to examine the effects of almonds on heart disease risk factors in individuals with 
type 2 diabetes.   
 
DESCRIPTION OF RESEARCH STUDY 
You have indicated to us that you are 25-75 years of age and have been diagnosed by a physician with type 2 
diabetes.  It is our understanding that you do not take insulin for your condition but you may take other 
prescription medications.  If there is a change to your prescription medication use during the 12-week study, 
please notify study personnel.  This study will initially involve the completion of a brief medical history 
questionnaire and a short dietary questionnaire.  At this time, your weight, height, and girth will be measured; 
your blood pressure will be taken; and, a drop of blood from a finger prick will be used to measure hemoglobin 
A1c.  You will be instructed to record all food and beverage intake on 12 days during the 12-week study.  This 
first meeting will take about 30 minutes.  You will be randomly assigned to the ‘almond’ group or to the ‘no 
dietary change’ group.  Participants in the almond group will consume 1.5 oz almonds daily during the trial.  
There are three additional visits (study visits 2, 3, and 4) that will last about 30 minutes and scheduled six weeks 
apart. On test days, you will travel to ASU (the Nutrition labs at the ASU Downtown campus or the Tempe 
campus) early in the morning and in a fasted state (no food or drink with the exception of water for >8 hours.)   
 
On the test days, you will have a blood sample drawn from an arm vein, and we will measure blood pressure, 
weight, and girth.  Food records will be collected at each test visit, and study foods will be provided.  About 50 
subjects will participate in this study.  A research nurse will draw blood using standard, sterile techniques.  
Finger pricks will be conducted under sterile conditions using disposable, retractable lancets.  Blood samples will 
be analyzed for biomarkers that are associated with the diabetic condition including glucose, insulin, cholesterol, 
and inflammation.   
 
RISKS 
Bruising of the skin or a feeling of faintness is possible during the blood draws. A registered nurse will draw the 
venous blood sample under sterile conditions and is trained to minimize these risks.  Although participants are 
screened for food allergies, it is possible that individuals may have allergic reactions to the almonds used in the 
study.   
 
BENEFITS  
This study will provide information regarding the usefulness of simple diet alterations for improving markers of 
heart disease risk in individuals with type 2 diabetes.  If desired, you will be provided with study results and your 
personal blood data at the end of the study.   Almonds will be provided at no charge.   
 
NEW INFORMATION 
If the researchers find new information during the study that would reasonably change your decision about 
participating, then they will provide this information to you.  
 
CONFIDENTIALITY 
All information obtained in this study is strictly confidential unless disclosure is required by law.  The results of 
this research study may be used in reports, presentations, and publications, but your name or identity will not be 
revealed.  In order to maintain confidentiality of your records, the investigators will use subject codes on all data 
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collected, maintain a master list separate and secure from all data collected, and limit access to all confidential 
information to the study investigators.  Plasma from blood samples will be stored for 5 years in freezers in the 
laboratories of the Nutrition Program at Arizona State University Downtown Campus after which time they will be 
disposed of as biohazard waste. 
 
WITHDRAWAL PRIVILEGE 
You may withdraw from the study at any time for any reason without penalty or prejudice toward you.  Your 
decision will not incur negative treatment to you by the researchers. 
 
COSTS AND PAYMENTS 
All study foods will be given to you during the study free of charge.  You will also receive a cash incentive ($25, 
$35, and $50) on study visits 2, 3 and 4 (total amount, $110). 
 
COMPENSATION FOR ILLNESS AND INJURY 
If you agree to participate in the study, then your consent does not waive any of your legal rights. However, in 
the event of harm, injury, or illness arising from this study, neither Arizona State University nor the researchers 
are able to give you any money, insurance coverage, free medical care, or any compensation for such injury.  
Major injury is not likely but if necessary, a call to 911 will be placed.  
 
VOLUNTARY CONSENT 
Any questions you have concerning the research study or your participation in the study, before or after your 
consent, will be answered by Dr. Karen Sweazea [480-965-6025] or Dr. Carol Johnston [602-827-2265].  
 
If you have questions about your rights as a subject/participant in this research, or if you feel you have been 
placed at risk, you can contact the Chair of the Human Subjects Institutional Review Board, through the ASU 
Research Compliance Office, at 480-965 6788.   
 
This form explains the nature, demands, benefits and any risk of the project.  By signing this form you agree 
knowingly to assume any risks involved.  Remember, your participation is voluntary.  You may choose not to 
participate or to withdraw your consent and discontinue participation at any time without penalty or loss of 
benefit.  In signing this consent form, you are not waiving any legal claims, rights, or remedies.  A copy of this 
consent form will be given to you.   
 
Your signature below indicates that you consent to participate in the above study.   
 
 
___________________________ _________________________ ____________ 
Subject's Signature   Printed Name    Date 
 
 
___________________________ _________________________       
Contact phone number              Email    
 
 
INVESTIGATOR’S STATEMENT 
"I certify that I have explained to the above individual the nature and purpose, the potential benefits, and possible 
risks associated with participation in this research study, have answered any questions that have been raised, 
and have witnessed the above signature. These elements of Informed Consent conform to the Assurance given 
by Arizona State University to the Office for Human Research Protections to protect the rights of human 
subjects. I have provided the subject/participant a copy of this signed consent document." 
 
 
 
Signature of Investigator____________________________________        Date_____________ 
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TYPE 2 DIABETES NUTRITION ASU
STUDY 
 
THE NUTRITION PROGRAM AT ASU IS RECRUITING VOLUNTEERS (25-75 y of 
age)  
THIS STUDY WILL TEST HOW ALMONDS AFFECT HEART DISEASE RISK 
INDICATORS IN INDIVIDUALS WITH TYPE 2 DIABETES.  IF YOU ARE A TYPE 
2 DIABETIC AND GENERALLY HEALTHY YOU MAY QUALIFY FOR THIS 
TRIAL.   
 
Participation will include: 
• Enrolling in a 12-week trial and consuming almonds daily if randomly assigned to this 
group.  One-half of participants will be assigned to a ‘no dietary change’ group.   
• Traveling to the ASU research site (either the downtown or Tempe campus) for 4 visits that 
will take about 30 minutes each to complete.   
• Fasting 12 hours and restricting exercise the night before three of the test visits. On these 3 
visits blood samples will be collected.  A finger prick will be performed on the initial visit.   
• There is a dietary nut restriction (aside from the study treatments) during the trial.   
 
All study foods will be given to you during the study free of charge.  
You will also receive cash incentives ($25, $35, and $50) on study 
visits 2, 3 and 4  
 
INTERESTED??  Please visit our recruitment site:   
https://www.surveymonkey.com/s/ASU_Diabetes_Study 
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APPENDIX E 
 
MEDICAL HISTORY QUESTIONNAIRE 
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Medical History Questionnaire   
 ID#________________ 
Age:________        Height:_______ft. 
_______in. 
Gender (please circle):  Female    Male     Weight:__________lbs. 
Smoker (please circle):  Yes No     Waist:________in. 
          
1.  Are you taking any medications regularly? (including aspirin, steroids, birth control, etc.)
 Y     N 
 If yes, what medications and how often? 
 
 
 
2. Do you currently take supplements? (vitamins, minerals, herbs, etc.)   
 Y     N 
 If yes, what supplements and how often? 
 
 
 
3. Do you take insulin or an oral diabetic control medication (e.g., metaformin)?  
 Y     N 
4. Do you know what your glycosylated hemoglobin A1C level is?    
 Y     N 
 If so, what is it?_______________________________ 
 
5. Has a doctor ever told you that you have any of the following conditions? 
       Heart disease?  Y     N     Thyroid problems?
 Y     N 
       Kidney disease?  Y     N     Cancer?  
 Y     N 
       Liver disease?  Y     N     High blood pressure?
 Y     N 
To be 
completed 
by 
investigator 
  TURN OVER  
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       Food Allergy?  Y     N (if yes, what type?)______________________________ 
       Type 2 Diabetes?                Y     N (if yes, when were you diagnosed?)_________________ 
       Other chronic conditions?__________________________________________________ 
 
6. Are you pregnant or planning on becoming pregnant in the next 16 weeks?  
 Y     N 
7. Are you currently breast-feeding?       
 Y     N 
8. Have you ever fainted at a blood draw?      
 Y     N 
Are you willing to participate in a blood draw?     
 Y     N 
 Have you donated blood in the past 8 weeks?     
 Y     N 
9. Will you be willing to consume 1.5 ounces of almonds 5-7 times per week for 12 weeks?
 Y     N 
 
10. Would you be able to restrict nut consumption (aside from that pertaining to the study 
       to 2 servings per week for 12 weeks?                                                                                            
 Y     N 
 
11. Do you follow a specific diet? (weight loss/gain, vegetarian, low-fat, etc.)  
 Y     N 
 
12. Are you willing to drive or take the Phoenix light rail (metro system) to either the ASU  
    Tempe or downtown Phoenix campus for a fasting blood draw on 3 separate occasions? 
 Y     N 
 
13. Will you have a problem fasting overnight (10-12 hr) prior to the blood draw? 
 Y     N  
 
14. Will you be able to maintain your typical lifestyle/activities during the trial?  
 Y     N 
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15. Over a 7 day period, how often do you engage in any regular activity long enough to work up 
a sweat   
      (e.g., heart beats rapidly)?_________________ How often do you exercise moderately per    
      week?___________ 
 
16. Please circle the total time you spend in each category for an average week. 
 
               Light activities such as: slow walking, golf, easy swimming, gardening, etc. 
           Hours per week: 0   1   2   3   4   5   6   7   8   9   10+ 
               Moderate activities such as: moderate walking, cycling, swimming, weight lifting, etc. 
           Hours per week: 0   1   2   3   4   5   6   7   8   9   10+ 
                Vigorous activities such as: fast walking, jogging, cycling, heavy/intense weight lifting, 
etc. 
           Hours per week: 0   1   2   3   4   5   6   7   8   9   10+ 
 
17. Please describe any other medical conditions or situations that may affect you ability to 
participate  
       in a research trial (i.e., pregnancy, infections, travel, deadlines, etc.). 
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APPENDIX F 
 
MONO-UNSATURATED FATTY ACID QUESTIONNAIRE 
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n-3 FFQ Calculation Template 
    Ritter-Gooder PK, Lewis NM, Heidal K, et al. Validity and Reliability of a Quantitative Food Frequency 
Questionnaire Measuring Omega-3 Fatty Acid Intakes in Cardiac Patients in the Midwest. JADA 
2006;106:1251-1255 
      
Possible values 
 
0,0.5,1,1.
5** 
1,3,6,14,22,30,6
0*** 
  Food Item MUFA Content in 
Grams/Medium 
Serving* 
Portion 
Size Frequency 
 
Total 
value 
Pickled Herring 5.500 0 0 
 
0 
Halibut, baked 5.000 0 0 
 
0 
Mackerel 2.400 
    Sablefish 3.800 
    Catfish, baked 3.400 0 0 
 
0 
Vegetable oil, sunflower or 
safflower, high oleic 70% 
12.000 
0 0 
 
0 
Hazelnut oil 12.000 0 0 
 
0 
Olive Oil 10.000 0 0 
 
0 
Shortening 9.000 0 0 
 
0 
Avocado oil 10.000 
    Almond oil 9.000 
    Margarine, hard 9.000 
    Peanut Oil 7.100 0 0 
 
0 
Cream substitute 1.830 0 0 
 
0 
Egg yolk, raw 2.450 0 0 
 
0 
Whipping Cream 2.100 0 0 
 
0 
Macadamia nuts 12.780 0 0 
 
0 
Hazelnuts or Filberts 10.480 0 0 
 
0 
Pecans 9.020 0 0 
 
0 
Almonds 7.500 0 0 
 
0 
Mixed Nuts without Peanuts 7.660 
0 0 
 
0 
Cahsew butter 10.000 0 0 
 
0 
Cashew nuts 6.770 0 0 
 
0 
Pistachio nuts 5.600 0 0 
 
0 
Sesame Seeds 5.200 0 0 
 
0 
Brazilnuts 5.600 0 0 
 
0 
Tahini 7.000 0 0 
 
0 
Peanut butter with Omega-3 12.000 
0 0 
 
0 
Peanuts 6.770 0 0 
 
0 
Peanut butter, chunky style 
(regular) 
8.000 
0 0 
 
0 
Peanut butter , smooth (regular) 6.000 
0 0 
 
0 
Kidney beans 4.370 0 0 
 
0 
Falafel 5.400 0 0 
 
0 
Olives, black 4.900 
    Olives, green from jar 5.750 
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Avocado, fresh, 1 whole 14.040 
    Foie gras 3.300 0 0 
 
0 
Beef, ribs, short ribs 5.600 0 0 
 
0 
Beef, ground 70% lean 8.800 0 0 
 
0 
Beef, corned beef, brisket 8.400 0 0 
 
0 
Pork, salt pork, cured 3.570 0 0 
 
0 
Pork, cured ham 5.300 0 0 
 
0 
Pork, bacon (2 pieces) 3.780 0 0 
 
0 
Bacon drippings 5.140 0 0 
 
0 
Pork chop, loin, shoulder 4.110 0 0 
 
0 
Bologna 2.200 0 0 
 
0 
Hot dogs, beef or pork 5.880 0 0 
 
0 
Hormel Spam 8.110 0 0 
 
0 
Bratwurst, pork 11.340 0 0 
 
0 
Beef, smoked sausage 8.800 0 0 
 
0 
Polish sausage 10.300 0 0 
 
0 
Itailian pork sausage 8.420 0 0 
 
0 
Lamb, chop lean and fat 7.440 0 0 
 
0 
Lamb, ground 9.940 0 0 
 
0 
Lamb, roasted 7.200 0 0 
 
0 
Beef sticks 5.230 0 0 
 
0 
Potatos chips, made with 
partially hydrogenated oil 
4.800 
0 0 
 
0 
Trail mix with chocolate chips, 
nuts, and seeds 
7.500 
0 0 
 
0 
Trail mix, regular 6.250 0 0 
 
0 
Beef jerky 2.700 0 0 
 
0 
Pork skins 2.010 0 0 
 
0 
Puff pastry 6.290 0 0 
 
0 
Nabisco, nilla pie crust 3.400 0 0 
 
0 
Cookies, shortbread 3.320 0 0 
 
0 
Doughnuts 4.130 0 0 
 
0 
Danish pastry 3.100 0 0 
 
0 
Pie crust, made with enriched 
flour 
2.400 
0 0 
 
0 
Cookies, chocolate sandwich 4.800 
0 0 
 
0 
Cookies, peanut butter 4.800 0 0 
 
0 
Pecan pie 8.430 0 0 
 
0 
Cookies, sugar 3.900 0 0 
 
0 
Pumpkin seeds 0.020 0 0 
 
0 
Ground Flaxseeds 2.000 0 0 
 
0 
Chia seeds 1.110 0 0 
 
0 
Poppy seeds 0.030 0 0 
 
0 
Banana bread 0.090 0 0 
 
0 
Pumpkin bread 0.480 0 0 
 
0 
Whole wheat bread 0.010 0 0 
 
0 
White bread 0.130 0 0 
 
0 
Oatmeal 0.020 0 0 
 
0 
Uncle Sams Cereal 1.200 0 0 
 
0 
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All-bran 0.040 0 0 
 
0 
Special K 0.010 0 0 
 
0 
Cream of Wheat 0.010 0 0 
 
0 
Wheat Germ 0.800 0 0 
 
0 
Miracle whip 0.290 0 0 
 
0 
Flax oil 2.510 0 0 
 
0 
Soybeans 1.450 0 0 
 
0 
Garbanzo beans 0.040 0 0 
 
0 
Navy beans 0.190 0 0 
 
0 
Lentils 0.040 0 0 
 
0 
Tofu 0.300 0 0 
 
0 
Soy milk 0.240 0 0 
 
0 
Pinto beans 0.340 0 0 
 
0 
Baked beans 0.160 0 0 
 
0 
Baked beans with pork 0.040 0 0 
 
0 
Refried Beans/frijoles 0.040 0 0 
 
0 
Red Kidney beans 0.080 0 0 
 
0 
Blackeyed peas 0.170 0 0 
 
0 
Great Northern beans 0.020 0 0 
 
0 
Lima beans 0.010 0 0 
 
0 
Fresh Spearmint 0.020 0 0 
 
0 
Fresh Peppermint 0.010 0 0 
 
0 
Monthly total 
    
0 
Daily total 
    
0 
      
      * Food ProcessorVersion 8.1, 
2003, ESHA Research 
     ** 0.5= 1/2     portion          1.0= 
1portion     1.5= 1 1/2 portion 
     ***  1= once a month 
     3= less than once a week 
     6= 1-2 times/week 
     14=3-4 times/week 
     22= 5-6 times/week 
     30= daily 
     60= more than once/day 
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APPENDIX G 
 
3-DAY DIET RECORD SHEET 
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DIETARY INTAKE RECORD 
 
Name: ______________________________ Date: _____________Weight (lbs): ______ 
 
TIME OF 
MEAL FOOD ITEM DESCRIPTION AMOUNT 
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TIME OF 
MEAL FOOD ITEM DESCRIPTION AMOUNT 
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Supplements Taken – List brand, dosage (potency), number of tablets/amount: 
 
TIME OF 
MEAL FOOD ITEM DESCRIPTION AMOUNT 
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APPENDIX H 
 
DEFAULT FOOD ITEMS FOR DIET ANALYSES   
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Food Item Food Processor Name 
ESHA 
Code 
   
SAUCES, OILS, JAMS, 
CONDIMENTS     
Alfredo Sauce Alfredo Sauce-Cnd 9103 
Balsamic vinegar Vinegar, balsamic 53457 
BBQ sauce Sauce, barbecue, original 4936 
Butter, regular  8000 
Butter, unsalted Butter, unsalted 8025 
Caramel topping Caramel topping 23070 
Creamy garlic dressing Salad dressing, Italian, garlic, creamy, rducd cal 8538 
Curry sauce Sauce, curry, prep f/recipe 53016 
Dijon mustard Mustard, dijon 27058 
Extra virgin olive oil Oil, olive, extra virgin 8361 
Fat free ranch dressing Salad dressing, ranch, fat free 8493 
Ginger dressing Salad dressing, lemongrass ginger 12931 
Grape jelly Jelly, grape (1T = 1 svg) 91451 
Green sauce Sauce, green 13486 
Honey Honey, strained/extracted 25001 
Honey mustard Mustard, honey, squeeze btl 92240 
Hot Sauce Hot pepper sauce 53470 
Jelly Jelly  23003 
Ketchup  Ketchup  27000 
Ketchup, packet Ketchup, pkt 9153 
Lemon juice Juice, lemon, fresh 3068 
Marinara Sauce Marinara pasta sauce-jar 53336 
Margarine Margarine, hard 44966 
Mayonnaise Dressing, mayonnaise type 8021 
Miracle whip Dressing, miracle whip 8479 
Miso sauce Sauce, miso 7563 
Mustard Mustard, deli, squeeze btl 91811 
Non-dairy creamer Creamer, non-dairy 517 
Oil and vinegar Salad dressing, vinegar & oil, classic, D-5, FS 8191 
Poppy seed dressing Salad dressing, poppy seed, creamy 44949 
Ranch dressing Salad dressing, ranch 8555 
Red Wine Vinaigrette Red Wine Vinegar & oil dressing 8595 
Salsa Salsa 53676 
Seasoned Salt Season-all Seasoned salt 91928 
Soy Sauce Soy sauce f/soy 53063 
Soybean oil Oil, soybean 44893 
Spicy brown mustard Mustard, spicy brown 93388 
Splenda pkt Sweetener, sucralose, pkt, consumer use only 63253 
Sriracha Hot Chili Sauce f/Mature Red Peppers 92173 
Strawberry jelly Jelly, strawberry 23294 
Sugar White granulated sugar 25006 
Sweet and Sour dressing Salad dressing, sweet and sour 44701 
Syrup, light Syrup, pancake, light, rducd cal 25223 
Teriyaki sauce Marinade, teriyaki sauce 53004 
Thousand island dressing Salad dressing, thousand island 8024 
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Vegan mayonnaise Dressing, mayonnaise, light, eggless 44859 
Worcestershire Sauce Worcestershire sauce 53099 
   
BEVERAGES     
Aloe Vera Juice Juice, aloe vera 7385 
Beer, Amber Ale Beer, Amber Ale 34066 
Beer, Hefeweizen Beer, Hefeweizen 22845 
Beer, Light Beer, light 22621 
Chai tea Tea, chai, original brewed w/water only 20883 
Chamomile tea Tea, herbal, chamomile, brewed 20118 
Coffee Coffee, brewed w/tap water 20012 
Cola Soda, cola 20147 
Cranberry Juice Juice, cranberry 4986 
Creamer Half and half 500 
Diet Cola Soda, cola, diet 20150 
Diet Dr. Pepper Soda, Dr Pepper, diet 4797 
Dr. Pepper Soda, Dr Pepper 4796 
Green tea Tea, green, brewed 20887 
Herbal tea, caffeine free Tea, herbal, caffeine free, brewed 20909 
Hot chocolate  33290 
Iced tea, Diet Diet lemon iced tea w/Asp 20540 
Iced tea, Sweetened Sweetened lemon iced tea 21031 
Iced tea, Unsweetened Tea, iced, unswtnd, pitcher style, can/btl 20542 
Izze Esque Juice drink, lemon, sparkling 14127 
Latte, lowfat Latte w/lowfat milk 20668 
Lemonade Drink, lemonade 20745 
Long Island iced tea Mixed drink, Long Island iced tea 22568 
Monster Energy Drink Energy drink w/Caff & Vit B 63337 
Protein Drink, Canned or Bottle HiProtein Van Supplement Drink-Can/Btl 62795 
Red wine Wine, red 22501 
Seltzer soda Soda, seltzer 4791 
Soy latte Coffee, soy latte 20921 
Sports Drink Sports Drink-Btl 20142 
Sports Drink, Blue MountainBlast Sports Drink-Can/Btl 20560 
Sports Drink, Lemon-Lime Lemon-lime Sports Drink-Btl 20646 
Sports Drink, Low Calorie Low Calorie Fruit Sports Drink 62967 
Sports Drink, Orange Orange Sports Drink-Can/Btl 20561 
Sugar free Red Bull Drink, energy, sugar free, can 63628 
Tap water Water, tap 21134 
Vitamin Water Vitamin Supreme Juice 20718 
Vodka Vodka, 94 proof 22641 
Whiskey Whiskey, 80 proof 22670 
White wine Wine, white, med 22504 
   
MEAT, EGGS, NUTS, SOY AND 
BEANS     
Almonds Nuts, almonds, dry rstd, salted, whole 4571 
Bacon Cured bacon-microwaved 92207 
Bean Burrito with Cheese Bean Burrito w/cheese 57576 
Beef, ground Beef ground hamburger 20% fat- pan browned 58124 
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Black bean burger Vegetarian meat, burger, soy, black bean & salsa 7718 
Black beans Beans, black, cnd 7168 
Blueberry soy yogurt Yogurt, soy, blueberry 71579 
Carne Asada Steak Beef skirt steak 58095 
Cashews Nuts, cashews, lightly salted, whole, svg 14504 
Chicken Breast, Grilled, Diced Grilled Chicken breast-Dice 81203 
Chicken, Sauteed, Skinless Chicken lt meat w/o skin- fried 15031 
Chicken Breast, Baked Original chicken breast-bkd, original, crispy 49168 
Chicken Breast, breaded Breaded chicken breast patty 81223 
Chicken, Chipotle Chicken thigh Broil/Fry w/o skin- roasted 15012 
Chicken Strips, breaded Chicken strips-breaded 81318 
Edamame Soybeans, edamame, ckd 9342 
Egg, hard boiled Hard Boiled Eggs, Lrg 19510 
Egg, fried  Fried whole egg- Large 19509 
Egg, fried in vegetable oil Egg- fried with vegetable oil 19573 
Egg, white, cooked Egg whites-cooked 19522 
Garbanzo beans Beans, garbanzo, cnd 9982 
Ham, deli sliced Deli cooked ham lunchmeat 11814 
Hot Dog, Beef Beef hot dog 58153 
Hummus Spread, hummus 7081 
Lamb Lamb chop 13512 
Lentil salad Dish, rice pilaf, lentil, dry 38639 
Light vanilla soy milk Soy milk, vanilla, light 7779 
Liquid eggs Egg substitute, new 19581 
Low fat vanilla soy milk Soy milk, vanilla, low fat 21068 
Mixed nuts Nuts, mixed, deluxe 14358 
Pastrami, beef, lunchmeat Cured beef pastrami- thin slc 57955 
Peanut butter Peanut butter, natural, creamy 62944 
Peanut butter, chunky, reduced fat Peanut butter, crunchy, reducd fat (2T = 1 svg) 62939 
Peanut butter, chunky, regular Natural peanut butter, chunky 62945 
Peanuts Nuts, peanuts, dry rstd, salted  (5.3 oz/cup) 4541 
Pine nuts Nuts, pine, pignolia, dried 4529 
Pinto beans Beans, pinto, cnd 7124 
Pistachio Nuts, pistachio, raw 4521 
Pot Roast Beef rib pot roast select Ln 1/4" tr-Rstd 10977 
Protein Drink, Vanilla, Canned HiProtein Van Supplement Drink 62795 
Protein Powder, Soy Soy Protein Powder-DryScp  (1 scp [1/3 cup]=35g) 62696 
Protein Powder, Whey Vanilla Whey Protein Isolate Pwd  (1/4 cup = 26.4g) 63320 
Raspberry soy yogurt Yogurt, soy, raspberry 71585 
Refried beans Dish, refried beans, cnd 7160 
Roast Beef, Deli Sliced Deli Medium Roast Beef Lunchmeat 11818 
Salami Genoa Salami 17344 
Shrimp Shrimp, mixed species, raw, med. 19125 
Soy bacon Vegetarian meat, Canadian bacon, soy, sliced 8838 
Soy creamer Creamer, soy milk, plain 54315 
Soy latte Coffee, soy latté, 11 fl. oz svg 20926 
Soy meat Vegetarian, protein, textured, TVP, Nutrisoy 52259 
Soy milk, chocolate Soy milk, chocolate 20920 
Soy milk, plain Soy milk, plain 20916 
Soy nuts, salted Soy nuts, salted 8877 
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Soy yogurt Yogurt, soy 71572 
Sunflower seeds Seeds, sunflower 4038 
Tofu Tofu, firm 12888 
Trail mix Regular Trail Mix 44058 
Tuna Fish, tuna, light, w/water, chunk, cnd 19163 
Turkey, deli sliced Oven rst turkey breast lunchmeat- deli sliced 58173 
Vegan mozzarella cheese Cheese, substitute, mozzarella 13388 
Vegetarian baked beans Beans, baked, plain/vegetarian, cnd 7038 
Vegetarian chicken Vegetarian meat, protein, pces, svg 7528 
Vegetarian ham Vegetarian meat, veggie Ham, deli sliced, svg 91656 
Vegetarian sausage Vegetarian meat, sausage, breakfast links, fzn 57436 
Veggie burger Vegetarian meat, burger, Garden Veggie Patties, fzn 7722 
Veggie griller Vegetarian meat, burger, soy Griller 7751 
Vegetarian chicken nuggets Vegetarian meat, protein, nuggets, svg 8829 
Walnuts, raw Nuts, walnuts, English, dried, halves 4557 
Whey protein Protein, whey, conc 52260 
White kidney beans Beans, cannellini/white kidney, unsalted, cnd 9732 
Yellowfish tuna Fish, tuna, yellowfin, fillet, bkd/brld 17177 
   
GRAINS     
Bagel Bagel, plain, classic 8846 
Banana Nut cereal Cereal, Banana Nut Crunch 40278 
Biscuit Biscuit 9069 
Blue corn tortilla chips Chips, tortilla, blue corn 44301 
Blueberry bagel Bagel, blueberry 62740 
Blueberry Morning cereal Cereal, Blueberry Morning 40279 
Blueberry muffin Muffin, blueberry 8868 
Broccoli and cheese rice Dinner, rice, white & wild, broccoli & cheese sauce 57753 
Brown Rice Rice, brown, med grain, ckd 38082 
Butter Croissant, small Butter croissant-sml 71298 
Cereal Bar, Strawberry Strawberry filled cereal bar 40253 
Couscous Couscous, ckd (1/2c = svg) 38076 
Dinner roll Rolls, dinner, lrg 71351 
English muffin English muffin 28146 
Flaxseed, ground  63636 
Flour tortilla, x-large Flour tortilla, rtb, 12" (4 oz) = 3C 90650 
Flour tortilla, large Flour tortilla, rtb, 10" (2.54 oz) = 2.5C 42025 
Flour tortilla , medium Tortilla, flour, rtb, 7" to 8"  (1.73 oz) = 1.75C 42026 
Flour tortilla, taco size Tortilla, flour, soft taco 42703 
Fried rice Fried rice w/bean sprouts & scallions 23938 
Granola bar Bar, granola, oats 'n honey  (1C) 47592 
Granola bar, chocolate Chewy chocolate chip granola bar 47103 
Granola  Oats & Honey Granola 61528 
Hamburger bun Buns, hamburger 42020 
Hot dog bun Hotdog/frankfurter bun 42021 
Kashi cereal Cereal, Autumn Wheat 61388 
Oatmeal, blueberry Cereal, hot, oatmeal, blueberry, inst, pkt 14288 
Oatmeal, plain Cereal, hot, oatmeal, plain, inst, pkt 40468 
Oatmeal, dry Quick hot oats oatmeal-dry (20g=1C) 40467 
Pancake, blueberry Pancakes, blueberry, prep f/recipe, 6" 45118 
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Pancakes Pancakes, plain, prep f/recipe, 6" 45117 
Panini/Ciabatta bread Italian bread- med slc 71219 
Peanut butter granola bar Soft peanut butter granola bar 23108 
Pita bread Bread, pita, white, unenrich, 6 1/2"  (2.12 oz) 42286 
Popcorn Popcorn, low fat, microwave 14973 
Pretzels, tiny twists, classic Pretzels, tiny twists, classic style 14390 
Puffins Peanut Butter cereal Cereal, Puffins, peanut butter 61495 
Rice cake Rice cake, plain 44016 
Rye bread Bread, rye, Jewish 72292 
Shredded Wheat cereal Cereal, Shredded Wheat, spoon size 40287 
Sourdough Bread, sourdough, med slice 71210 
Spanish rice Dish, rice, spanish 53670 
Strawberry Fields cereal Cereal, Strawberry Fields 61389 
Sun Chips, French onion Snack, multigrain, french onion, svg 44257 
Taco salad shell Taco Salad Shell 13474 
Taco shells Taco shells 71544 
Tater tots Tater tots, abc's, fzn 70598 
Top Ramen Soup, Ramen noodles, miso flvr, dry pkg 91729 
Tortilla Chips   44264 
Tortilla, corn Tortilla, corn, white, 6” 33419 
Tortilla chips, plain  53695 
Tortilla Chips, Doritos Nacho flavored tortilla chips  (1 oz= 12 chips) 44005 
Triscuit crackers Crackers, whole wheat, original 43584 
Vanilla Almond cereal Cereal, Shredded Oats, Vanilla Almond 61488 
Waffles, whole grain Waffles, 8 grain, fzn 12460 
Wheat crackers Crackers, wheat, original 43581 
Wheat dinner roll Rolls, dinner, wheat 42160 
Wheat hoagie roll whole wheat hoagie roll-med  (3.32 oz) 71358 
Wheat pita bread   42080 
White bread Bread, white, hearty 42475 
White rice Rice, white, long grain, ckd 38013 
White sub roll, 5"-6" Italian /white bread-6" SUB    (2.5 oz) 91792 
Whole grain bread     62798 
Whole grain bread, ezekiel Bread, sprouted, whole grain, flourless, svg 72930 
Whole wheat bread Bread, whole wheat, 100% 72301 
Whole wheat pasta Pasta, macaroni, whole wheat, ckd 38110 
Whole wheat tortilla Tortilla, whole wheat (1.65 oz) = 1.7C 71938 
Wild long grain rice Dish, rice pilaf, long grain & wild, dry 38614 
Yakisoba noodles Japanese soba noodles 38094 
   
DAIRY     
American cheese Cheese product, American, past, proc, slice 47824 
Cheddar cheese, sliced Cheddar cheese-slc 47864 
Cheddar cheese, shredded Cheddar chesse-shredded 1008 
Cheese, mixed Cheese, cheddar & monterey jack, shredded 47771 
Chocolate ice cream, low fat Ice cream, chocolate, 98% fat free 72151 
Colby cheese, slice Cheese, colby jack, slice 47784 
Colby and Jack cheese, shredded Colby & Monterey Jack cheese-Shred 1333 
Cottage cheese Cottage cheese, 1% fat  1047 
Cream cheese Cream cheese 1015 
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Cream cheese, low fat Cream cheese low fat 1098 
Fat free half and half Cream, half and half, fat free 54378 
Feta cheese Cheese, feta, crumbled 1238 
Goat cheese Cheese, goat, hard 1078 
Half and Half Cream, half and half  500 
Light Swiss cheese Cheese, wedge, creamy swiss original light 48339 
Milk 1% Milk, 1%, w/add Vit A & D 4 
Milk 2% Milk, 2%, w/add vit A & D 2 
Milk-skim Milk, nonfat/skim, w/add Vit A 6 
Milk-whole 3.25% whole milk 1 
Mixed berry ice cream, low fat Ice cream, strawberry, old fash, low fat 1738 
Mozzerella Cheese, shredded   1058 
Parmesan cheese Cheese, parmesan, dried, grated 1252 
Pepper Jack Cheese   48294 
Provolone cheese Cheese, provolone, slice 47900 
Pudding, banana Pudding, banana, snack cup 57989 
Sour cream Sour cream 555 
Soy butter Butter substitute, plain, soy, vegetarian 90961 
Soy cheese Cheese substitute, cheddar, soy 47983 
String cheese, Low Fat Cheese, mozzarella, string, low moist, part skim 48255 
Swiss cheese Cheese, swiss, aged, Deli Thin, slice 48245 
Vanilla frozen yogurt Frozen yogurt, vanilla 71517 
Vegan cheddar cheese Cheese substitute, cheddar 13387 
Vegan sour cream 
Sour cream sub, Sour Supreme, Better Than (3T = 1 oz 
wt) 13697 
Yogurt, blueberry Yogurt, blueberry mist, lowfat, indv 72536 
Yogurt, lemon custard Lowfat lemon burst yogurt 72506 
Yogurt, peach Yogurt, peach cobbler, lowfat 72467 
Yogurt, strawberry  Lowfat classic strawberry yogurt 72809 
Yogurt, strawberry, fat-free Light Nonfat Strawberry Yogurt 13350 
Yogurt, vanilla Lowfat Vanilla Yogurt 2015 
   
VEGETABLES      
Artichoke Artichoke, French, ckd, drained, med 4436 
Artichoke heart Artichoke, hearts, w/water, cnd 319 
Asparagus Asparagus, cnd, drained, 5" long 5007 
Avocado Avocado, medium 3658 
Baby potatoes Potatoes, white, baby, ckd 9366 
Beet Beets, fresh, whole, 2" 5572 
Broccoli Broccoli, florets, fresh 5556 
Broccoli, cooked Broccoli chopped cooked 5028 
Broccoli, sauteed Stir fried broccoli 5654 
Brussel sprout Brussel Sprouts, fresh 5032 
Cabbage, red Cabbage, red, fresh, chpd 6766 
Carrot Carrots, fresh, lrg, 7 1/4" - 8 1/2" long 90423 
Carrots, baby Carrots, fresh, baby, med  (14 ea = 1 cup) 5439 
Carrots, shredded Carrots, fresh, grated 5046 
Carrots, sliced  (4.2 oz/cup) Smooth sliced carrots 1799 
Carrots, whole, cooked Whole carrots cooked-drnd  (1F=78g) 5048 
Celery stalk Celery, stalk, fresh, med 5704 
Cherry tomatoes Tomatoes, red, cherry, fresh, year round avg 90530 
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Coleslaw Cole Slaw, classic 69200 
Corn on the cob Corn, cob, 5.5", Simply Sweet, 80% ckd, iqf, FS 1812 
Cucumber Cucumber, fresh, med 5705 
Cucumber, sliced  (6 slices=.33 cup) Fresh sliced cucumber w/peel 5071 
Fennel bulb Fennel, bulb, fresh 5449 
French Fries, medium French fries, medium (1 med=1.5 cup) 81439 
French Fries, small French fries, small 81438 
French Fries, Waffle Waffle French Fries, Sml  (Med=1.5, Lrg=2) 7973 
Frozen Vegetables Vegetables, fzn 6391 
Garlic Garlic, cloves, fresh 26005 
Green beans Snap beans, green, cnd, drained 6750 
Green beans, cooked Green snap beans ckd w/salt-drnd 5856 
Green bell pepper, chopped Peppers, bell, green, sweet, fresh, chpd 5124 
Green bell pepper, medium Fresh green bell pepper-med  (1/2 ea=1F) 6846 
Iceberg, leaf Fresh Iceberg Lettuce-Med Leaf  (7 leaf=1F) 90446 
Iceberg, shredded Shredded iceberg lettuce 9316 
Kale (4oz) = 1 bunch? Cabbage, kale, fresh, chpd (1 stalk = 1 cup) 5208 
Kettle potato chips Chips, potato, original, svg 14316 
Lettuce, Shredded Shredded Lettuce Leaf 9328 
Mashed potato Mashed Potatoes, fast food 6185 
Mushroom Mushrooms, brown, fresh 440 
Mushroom, Diced, Cooked Mushroom pieces- stir fried w/o oil 5658 
Mushroom, Sliced, Raw   5090 
Onion, chopped Onion, white, fresh, chpd  (1/2 cup = 68.8g) 5101 
Onion, white, cooked White onion cooked drained whole-med  (1F=105g) 5110 
Onion, white, sliced 
Fresh whit onions med slce-1/8" (5slices=1F; .5 
cup=68g) 90460 
Peas, frozen Peas, green, ckd f/fzn, drained 5118 
Pico de gallo Salsa, pico de gallo ( 1 svg = 1/2 c) 28103 
Potato   Potatoes, baked, med, 2 1/4" to 3 1/4" 5334 
Potato chips Chips, potato, original, svg 44236 
Potato chips, BBQ BBQ potato chips 61064 
Potato, diced, cooked Peeled potato, diced-ckd 5136 
Radish Fresh red radish- med  (2 ea=1F) 5143 
Red Bell Pepper, medium Peppers, bell, red sweet, med 2 3/4" x 2 1/2" 6989 
Red Bell Pepper, sliced Peppers, bell, red sweet, fresh, sliced  (61g=1/2 cup) 5295 
Red onion Onion, red, fresh, med slice, 1/8"  (5sl=1F;.5cup=68g) 90465 
Romaine lettuce  Lettuce, romaine, fresh, leaf  9331 
Salsa Salsa, prep from recipe 27020 
Salad Salad, leaf & romaine 69204 
Snap peas  (2.2 oz/cup) Peas, sugar snap, stir fry blend, 80% ckd, iqf, FS 1845 
Spinach, chopped Spinach, fresh, chpd 5146 
Spinach leaves, fresh Fresh spinach leaves 6863 
Sprouts Sprouts, alfalfa, fresh 5010 
Sweet potato Sweet potato, dark orange, fresh, 5" 5809 
Tomato Tomatoes, fresh, med 5718 
Tomato, diced Fresh red tomatoes YearRoundAvg-Chpd/Slc 5170 
Tomato, sliced 
Fresh Red Tomatoes YrRndAvg Med Slc-1/4"(5 
slices=1F) 5173 
Tomato sauce Tomato sauce, cnd 5180 
Vegetables, mixed, thai blend Thai stirfry mixed vegetables  (1/2 cup= 2oz) 9670 
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Vegetables, roasted 
Vegetables, peppers & onions, flame rstd, 80% ckd, iqf, 
FS 715 
Zucchini Squash, zucchini, baby, med, fresh 90604 
   
FRUIT     
Apple, Large Fresh Apples w/Peel-Lrg 3 1/4" (1.5F) 3001 
Apple, Medium Apples, fresh, med, 3" 3000 
Apple, Small Fresh apples w/peel-sml 2 1/2" (.75F) 71077 
Apple juice Juice, apple 793 
Applesauce Applesauce, gravenstein, unswtnd, cnd 3924 
Apricot, fresh Apricots, fresh, whole 14909 
Apricots, dried Apricots, dried 71688 
Avocado, medium Avocado, fresh, med, FDA 3852 
Banana, large Fresh lrg banana-8" to 8 7/8" long  (1.25F) 3659 
Banana, medium Banana, fresh, med, 7" to 7 7/8" long 3020 
Blackberries Blackberries, fresh 3024 
Blueberries Blueberries, fresh 3029 
Blueberries, frozen Blueberries-fzn 9647 
Cantaloupe Melon, cantaloupe, fresh, cubes 3075 
Cherries Cherries, fresh 3373 
Cranberries Cranberries, fresh, whole 3039 
Cucumber Cucumber, fresh, med 5705 
Cucumber, sliced Fresh sliced cucumber w/peel  (52g=1F;6 sli=.25cup) 5071 
Dates, fresh Dates, fresh 3374 
Frozen peaches Peaches, sliced, fzn 9650 
Fruit leather Fruit leather, sunberry burst 61581 
Fruit salad Salad, fruit, chilled, FS 52010 
Grapes Grapes, fresh, FDA (8 ea = 1/2 c) 3844 
Grapefruit Grapefruit, pink 3 ¾” 4888 
Grape Juice Concord grape juice 4985 
Guava Guave, fresh 3634 
Honeydew Melon, honeydew, fresh, 5 1/4" 71102 
Kiwi Kiwi, fresh, med, FDA   (6.2 oz/cup)  (2 ea=1F) 3858 
Lemon Lemon, fresh, med, FDA 3853 
Lime Limes, fresh, med, FDA 3857 
Mango Mango, fresh   (5.82 oz/cup) 71980 
Mango, frozen Mango, chunks, fzn 9801 
Nectarine Nectarines, fresh, med, FDA 3849 
Olive Olives, black, large, cnd 27009 
Orange Oranges, all types, fresh, med, 2 5/8" 3082 
Orange, small   3086 
Orange juice Juice, orange 1854 
Orange juice with Calcium Orange juice w/Calcium 3480 
Peach Peaches, fresh, med, FDA 3847 
Pear Pears, fresh, asian, 2 1/4" x 2 1/2" 3272 
Pineapple Pineapples, chunks, cnd, w/water 3737 
Pineapple/orange/banana juice Juice, pineapple orange banana, rtd 3992 
Plum Plums, fresh, med, FDA 3851 
Raspberries Fresh 3648 
Strawberries Strawberries, fresh, med, FDA   (3 whole=1/4 cup) 3846 
Strawberries, frozen unsweetened strawberries-fzn  (75g=1F) 3137 
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Tangerine Tangerines, fresh, med 71989 
Watermelon Watermelon, diced, fresh 3385 
   
MISCELLANEOUS     
Apple cinnamon toaster pastry Pastry, apple cinnamon, toaster style 12455 
Artichoke and spinach bites Dish, ravioli, spinach and artichoke filled, brd, FS 60769 
Bean Burrito w/cheese Bean burrito w/cheese  (5C) 57576 
Bean and Rice Burrito Organic bean & rice burrito-fzn 83097 
Beef Taco  56642 
Broccoli and cheddar soup Soup, broccoli cheddar cheese, rts, cnd 50895 
Broccoli soup Soup, broccoli, creamy 1790 
California Roll California Sushi roll 91813 
Cheeseburger Cheeseburger plaing-lrg 56648 
Cheese & spinach tortellini Dish, pasta, tortellini, spinach cheese, refrig 83187 
Cheese quesadilla Quesadilla, cheese 12866 
Chicken Quesadilla Chicken Quesadilla (2.5C) 72589 
Chicken Soft Taco Chicken Soft Taco   (1C,.5F) 7204 
Cheez-It reduced fat Crackers, cheese, rducd fat (10ea = 1 svg) 43812 
Chex Mix Snack, mix, bold party blend 44205 
Coconut milk Coconut, milk, fresh 4528 
Corn Dog Corn dog  (1.5C) 56668 
Crab cakes Crab cakes, make w/blue crab 19420 
Curry dinner Dish, tofu w/sour curry, Thai, prep f/recipe, svg 2997 
Egg roll Dish, egg roll, vegetable, ckd 15272 
Falafel Dish, falafel, prep f/recipe, patty, 2 1/4" 16138 
French Fries  23958 
Grilled cheese sandwich Sandwich, cheese, grilled 12818 
Guacamole Guacamole, California 44423 
Instant breakfast shake Instant Breakfast, French vanilla, no sug add, rtd, cnd 14722 
Lasagna Stouffer’s 21501 
Luna Bar, nutz over chocolate Bar, energy, nutz over chocolate 43709 
Macaroni & cheese Dish, macaroni & cheese 56681 
Minestrone soup Soup, minestrone 4835 
Mocha w/soy, small Coffee, mocha, w/soy milk 20923 
Pad Thai vegetarian Dish, pad Thai, w/rice noodles, vegetarian, rth 92069 
Pickle, sandwich slice Pickles, bread & butter, sandwich slice 9688 
Pizza for one Pizza, cheese, for one, fzn  (2.25C,.5F) 56782 
Pizza, cheese, large Cheese 16" large Pizza- slice (2C, .5F) 831 
Pizza, cheese, med Pizza, cheese, med, 12"  (1C, .25F) 56485 
Pizza, chicken,grn pepper & onion ChickenOn&GrnPpr 12"med slice (1C, .5F) 92479 
Pizza, individual 6" Pizza, cheese, 6" 57787 
Pizza, pepperoni, 14" Pepperoni 14" Lrg pizza-slc (1C,.25F) 92458 
Pizza, pepperoni, 1/6 of 12" Pepperoni pizza- 1/6 of 12"  (1.25C, .25F) 90795 
Pizza, pepperoni, 12", med Pepperoni pizza- 12" slice (.9C, 2 slices=.25F) 56490 
Pizza, spinach mushroom garlic (1.25C, .75F) 90787 
Pizza, thin crust Pizza, cheese, thin crust, 14" 93262 
Pizza, veggie Pizza, Veggie Lover's, med, 12"  (1.5C,1.25F) 57811 
Potato chips  53695 
Potato salad Salad, potato, picnic, FS 4842 
Spaghetti with meatballs Canned 92765 
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Spring roll Dish, spring roll, vegetable, Thai, prep f/recipe 2995 
Subway veggie sandwich, 6" Sandwich, veggie delite, w/white, 6" 69109 
Tortilla soup Tortilla soup w/toppings (1C,1F) 50713 
Vegetable burrito Burrito, veggie 56620 
Vegetable lasagna Dish, lasagna, vegetable, Mona's, FS 57841 
Vegetable quiche Dish, quiche, spinach, vegetarian 57514 
Vegetable sandwich, grilled Sandwich, rstd vegetable, pocket, fzn 81193 
Vegetable soup Soup, vegetable, vegetarian, cond, cnd 50509 
Vegetable summer rolls Thai vegetable spring roll  (1C,.5F) 2995 
Vegetable stir fry Dish, stir fry, rice & veg 70470 
Vegetarian baked beans Beans, baked, plain/vegetarian, cnd 7038 
Vegetarian bratwurst Vegetarian meat, sausage, bratwurst 91495 
Vegetarian chili Chili, vegetarian, cnd 7609 
Vegetarian corn dog Corn dog, vegetarian, fzn 8869 
Vegetarian sushi roll Sushi, vegetarian roll 92384 
   
DESSERT     
Baby Ruth, Funsize Candy bar, Baby Ruth, fun size 23269 
Brownie (2" square) Brownie, 2" square, fast food 47150 
Butterfinger, Funsize Candy bar, Butterfinger, fun size 23067 
Carob cookies Cookies, carob 47076 
Carrot cake Cake, carrot 12760 
Chocolate cake with frosting Cake, chocolate, w/chocolate icing, 1/8th of 18oz 16392 
Chocolate chip cookie Cookies, chocolate chip 47520 
Chocolate, Dark Candy, dark choc 92662 
Fortune cookie Fortune Cookie 91667 
Frozen Yogurt, Chocolate Frozen yogurt, chocolate, nonfat 72784 
Frozen Yogurt, Vanilla Vanilla frozen yogurt soft serve 2064 
Ice Cream, Cookies & Cream All Nat Cookies N cream ice cream 71482 
Ice Cream, Vanilla Vanilla ice cream 2004 
Kit Kat Candy bar, Kit Kat, 1.5oz bar 23060 
Licorice Candy, licorice 92656 
M & M candies Candy, milk chocolate 23045 
Mango ice cream Ice cream, mango 72700 
Oatmeal chocolate chip cookie Cookies, oatmeal, w/choc chip 92327 
Oatmeal cookie Cookies, oatmeal raisin 47656 
Popsicle, cherry Frozen dessert pop, cherry 72238 
Rice Krispies Treats Rice Krispies Treats, squares 44219 
Shortbread cookie, sugar free Cookies, shortbread, sugar free 93010 
Skittles candies Candy, Skittles, original, bite size 23431 
Small banana split Frozen dessert, banana split, sml 72140 
Sorbet Sorbet, strawberry 49197 
Sugar, brown  19334 
Tootsie, lollipop Candy, hard, lollipop, Tootsie Pop, asrtd flvrs, mini 92708 
 
